iron atom - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	iron atom	go back to main search page
Accession:	CHEBI:18248	browse the term
Definition:	An iron group element atom that has atomic number 26.
Synonyms:	related_synonym:	26Fe; Eisen; Fe; Formula=Fe; InChI=1S/Fe; InChIKey=XEEYBQQBJWHFJM-UHFFFAOYSA-N; SMILES=[Fe]; fer; ferrum; hierro; iron
	alt_id:	CHEBI:13322; CHEBI:24872; CHEBI:5974
	xref:	CAS:7439-89-6; DrugBank:DB01592; HMDB:HMDB0015531; KEGG:C00023
	xref_mesh:	MESH:D007501
	xref:	Reaxys:4122945; WebElements:Fe

show annotations for term's descendants Sort by:
Rat (1696) Mouse (1705) Human (1802) Chinchilla (0) Bonobo (0) Dog (5) Squirrel (0) Pig (2) Green Monkey (0) Naked Mole-rat (0) All
Genes (1696)

iron atom

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

multiple interactions

ABCC1 protein promotes the reaction [Nitric Oxide results in increased secretion of Iron]

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily G member 2

affects metabolic processing

ABCG2 protein affects the metabolism of Iron

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acyl-CoA binding domain containing 3

multiple interactions

Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]

NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380

G

acetylcholinesterase

multiple interactions

[teferrol results in increased abundance of Iron] which results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

aconitase 1

multiple interactions
affects metabolic processing

Iron inhibits the reaction [nickel chloride results in increased activity of ACO1 protein]; Iron inhibits the reaction [Nickel results in increased activity of ACO1 protein]
[Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein
ACO1 protein affects the metabolism of Iron

PMID:15893546 PMID:16039939 PMID:16877034 PMID:17194590

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

aconitase 2

multiple interactions
increases activity

[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical; [Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron; ACO2 protein affects the reaction [Paraquat results in increased abundance of Iron]; Iron deficiency promotes the reaction [Clofibrate results in increased expression of ACO2 protein]; Iron inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; Iron inhibits the reaction [Manganese results in decreased activity of ACO2 protein]
Iron results in increased activity of ACO2 protein

PMID:9675333 PMID:11969379 PMID:16162655 PMID:21517855

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

acyl-CoA synthetase family member 2

decreases expression

Iron deficiency results in decreased expression of ACSF2 mRNA

NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673

G

acyl-CoA synthetase long-chain family member 1

decreases expression

Iron deficiency results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

acyl-CoA synthetase long-chain family member 3

decreases expression

Iron deficiency results in decreased expression of ACSL3 mRNA

NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627

G

adhesion G protein-coupled receptor G1

decreases expression

Iron deficiency results in decreased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

alpha hemoglobin stabilizing protein

multiple interactions

AHSP protein binds to and affects the folding of and affects the stability of [HBA1 protein binds to Iron]

NCBI chr 1:182,879,901...182,885,508
Ensembl chr 1:182,880,076...182,885,506

G

A-kinase anchoring protein 13

decreases expression

Iron deficiency results in decreased expression of AKAP13 mRNA

NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]

PMID:17172471 PMID:32828744 PMID:33580994

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

5'-aminolevulinate synthase 2

increases expression

Iron results in increased expression of ALAS2 mRNA

NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519

G

albumin

multiple interactions

ALB protein affects the reaction [[Iron co-treated with Bicarbonates] results in increased abundance of Malondialdehyde]; ALB protein inhibits the reaction [[Iron co-treated with Phosphates] results in increased abundance of Malondialdehyde]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldolase, fructose-bisphosphate C

decreases expression

Iron deficiency results in decreased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

ankyrin repeat domain 22

increases expression

Iron deficiency results in increased expression of ANKRD22 mRNA

NCBI chr 1:231,639,035...231,670,537
Ensembl chr 1:231,639,314...231,670,381

G

ankyrin repeat domain 37

increases expression

Iron deficiency results in increased expression of ANKRD37 mRNA

PMID:16629162 PMID:23776592

NCBI chr16:46,268,933...46,271,971
Ensembl chr16:46,268,443...46,271,963

G

annexin A1

decreases expression

Iron deficiency results in decreased expression of ANXA1 mRNA

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A2

increases expression

Iron deficiency results in increased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

adaptor related protein complex 1 subunit sigma 3

decreases expression

Iron deficiency results in decreased expression of AP1S3 mRNA

NCBI chr 9:80,950,402...81,009,889
Ensembl chr 9:80,950,715...81,009,798

G

adaptor related protein complex 2 subunit alpha 1

multiple interactions

[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of AP2A1 mRNA

NCBI chr 1:95,384,306...95,414,170
Ensembl chr 1:95,384,309...95,414,147

G

apolipoprotein E

increases response to substance

APOE gene polymorphism results in increased susceptibility to Iron

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein H

decreases expression

Iron deficiency results in decreased expression of APOH mRNA

NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329

G

amyloid beta precursor protein

increases uptake
increases expression

Iron results in increased uptake of APP protein
Iron results in increased expression of APP mRNA

PMID:15993987 PMID:16308480

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 4

increases expression
multiple interactions

Iron deficiency results in increased expression of AQP4 mRNA
[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 mRNA; [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein; SB 203580 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; U 0126 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; Vitamin E inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]

PMID:16629162 PMID:30914277

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

AT-rich interaction domain 3B

increases expression

Iron deficiency results in increased expression of ARID3B mRNA

NCBI chr 8:58,193,268...58,240,901
Ensembl chr 8:58,193,418...58,238,318

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

ARNT protein affects the reaction [Iron deficiency results in increased activity of CP promoter]

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

arrestin domain containing 3

increases expression

Iron deficiency results in increased expression of ARRDC3 mRNA

NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978

G

ATM serine/threonine kinase

affects response to substance
affects abundance
multiple interactions

ATM protein affects the susceptibility to Iron
ATM protein affects the abundance of Iron
Iron results in increased phosphorylation of and results in increased activity of ATM protein

PMID:15336622 PMID:16959548

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase copper transporting alpha

affects metabolic processing
increases expression
multiple interactions
affects transport
decreases oxidation
increases response to substance

ATP7A protein mutant form affects the metabolism of Iron
Iron deficiency results in increased expression of ATP7A; Iron deficiency results in increased expression of ATP7A mRNA; Iron deficiency results in increased expression of ATP7A protein
[Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper
ATP7A mutant form affects the transport of Iron
ATP7A gene mutant form results in decreased oxidation of Iron
ATP7A gene mutant form results in increased susceptibility to Iron deficiency
[ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Iron; ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]; Iron deficiency inhibits the reaction [ATP7A gene mutant form results in decreased oxidation of Iron]

PMID:16629162 PMID:21852364 PMID:23174565 PMID:23776592 PMID:23814049 More...

NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354

G

ATPase copper transporting beta

increases abundance

ATP7B gene mutant form results in increased abundance of Iron

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

beta-2 microglobulin

multiple interactions
affects metabolic processing

[HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron
B2M protein affects the metabolism of Iron

PMID:16841247 PMID:17194590

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

BCL2-associated agonist of cell death

multiple interactions

[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein]

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

multiple interactions

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]

PMID:30626086 PMID:33285147 PMID:33393188

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL10, immune signaling adaptor

multiple interactions

[Arsenic co-treated with Iron] results in increased expression of BCL10 mRNA

NCBI chr 2:234,840,880...234,850,520
Ensembl chr 2:234,840,858...234,850,523

G

BCL2, apoptosis regulator

multiple interactions

[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein]

PMID:19620254 PMID:33285147

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]

PMID:19620254 PMID:27916511 PMID:30626086

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

BCL3, transcription coactivator

increases expression

Iron deficiency results in increased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

beclin 1

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of BECN1 protein; [Hydrogen Peroxide co-treated with [ferric ammonium citrate results in increased abundance of Iron]] results in increased expression of BECN1 protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bone morphogenetic protein 6

decreases abundance
increases expression
decreases expression
increases abundance

BMP6 protein results in decreased abundance of Iron
Iron results in increased expression of BMP6 mRNA
Iron deficiency results in decreased expression of BMP6 mRNA
BMP6 gene mutant form results in increased abundance of Iron

PMID:19252486 PMID:19252488 PMID:20164366

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

BCL2 interacting protein 3

increases expression

Iron deficiency results in increased expression of BNIP3 mRNA

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

calcium voltage-gated channel subunit alpha1 C

multiple interactions

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

calreticulin

increases expression

Iron results in increased expression of CALR mRNA; Iron results in increased expression of CALR protein

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calcium/calmodulin-dependent protein kinase II delta

multiple interactions

[Arsenic co-treated with Iron] results in increased expression of CAMK2D mRNA

NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178

G

caspase 3

multiple interactions

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; [Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CASP3 protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]

PMID:19620254 PMID:27916511 PMID:30626086 PMID:31678598 PMID:32828744 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions
decreases activity

Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein]; Iron promotes the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [mezerein results in decreased activity of CAT protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein]
Iron results in decreased activity of CAT protein
[Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of CAT protein; [ferrocene results in increased abundance of Iron] which results in decreased expression of CAT protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein; [teferrol results in increased abundance of Iron] which results in increased activity of CAT protein; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CAT protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein]; leonurine inhibits the reaction [Iron results in decreased activity of CAT protein]

PMID:12065085 PMID:12067571 PMID:12504893 PMID:17176674 PMID:20100038 More...

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

affects localization

Iron affects the localization of CAV1 protein

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

Iron deficiency results in increased expression of CCL2 mRNA
[Iron co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA; Iron promotes the reaction [[Copper co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA]

PMID:20302851 PMID:20368581

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CCL3 mRNA

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

increases expression

Iron deficiency results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin A2

multiple interactions

[Arsenic co-treated with Iron] results in decreased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

increases expression

Iron deficiency results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1; Iron results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1 protein

PMID:16629162 PMID:16890145 PMID:22649188

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin G2

increases expression

Iron deficiency results in increased expression of CCNG2 mRNA

NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830

G

cell cycle progression 1

increases expression

Iron deficiency results in increased expression of CCPG1 mRNA

NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430

G

centriole, cilia and spindle-associated protein

increases expression

Iron deficiency results in increased expression of CCSAP mRNA

NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753

G

CD109 molecule

increases expression

Iron deficiency results in increased expression of CD109 mRNA

NCBI chr 8:79,454,480...79,569,195
Ensembl chr 8:79,454,480...79,569,194

G

CD14 molecule

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; Vitamin D promotes the reaction [Iron deficiency results in increased expression of CD14 protein]

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD1d1 molecule

decreases expression

Iron deficiency results in decreased expression of CD1D1 mRNA

NCBI chr 2:172,423,582...172,427,089
Ensembl chr 2:172,423,582...172,427,089

G

Cd300a molecule

increases expression

Iron deficiency results in increased expression of CD300A mRNA

NCBI chr10:99,929,801...99,942,674
Ensembl chr10:99,929,801...99,942,674

G

CD36 molecule

decreases expression

Iron deficiency results in decreased expression of CD36 mRNA

PMID:16629162 PMID:19821111

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

Cd70 molecule

increases expression

Iron deficiency results in increased expression of CD70 mRNA

NCBI chr 9:2,006,563...2,009,715
Ensembl chr 9:2,006,563...2,009,715

G

CD74 molecule

decreases expression

Iron deficiency results in decreased expression of CD74 mRNA

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

CDP-diacylglycerol--inositol 3-phosphatidyltransferase

decreases expression

Iron deficiency results in decreased expression of CDIPT mRNA

NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1C

decreases expression

Iron deficiency results in decreased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

cyclin dependent kinase inhibitor 2D

increases expression

Iron deficiency results in increased expression of CDKN2D mRNA

NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674

G

cysteine dioxygenase type 1

multiple interactions

Iron binds to and results in increased activity of CDO1 protein

NCBI chr18:39,432,473...39,447,253
Ensembl chr18:39,432,474...39,447,296

G

CMT1A duplicated region transcript 4

increases expression

Iron deficiency results in increased expression of CDRT4 mRNA

NCBI chr10:47,625,470...47,657,493
Ensembl chr10:47,625,470...47,657,493

G

CDP-diacylglycerol synthase 1

decreases expression

Iron deficiency results in decreased expression of CDS1 mRNA

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

carboxyl ester lipase

increases expression

Iron deficiency results in increased expression of CEL mRNA

NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035

G

checkpoint kinase 2

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

chitinase 3 like 1

decreases expression

Iron deficiency results in decreased expression of CHI3L1 mRNA

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

cholinergic receptor nicotinic delta subunit

multiple interactions

[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of CHRND mRNA

NCBI chr 9:87,862,417...87,870,833
Ensembl chr 9:87,862,407...87,870,833

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]

PMID:17172471 PMID:33285147

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

claudin 2

increases expression

Iron deficiency results in increased expression of CLDN2 mRNA

NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838

G

colipase

increases expression

Iron deficiency results in increased expression of CLPS mRNA

NCBI chr20:6,620,529...6,622,709
Ensembl chr20:6,620,529...6,622,689

G

calponin 3

increases expression

Iron deficiency results in increased expression of CNN3 mRNA

NCBI chr 2:209,518,948...209,550,107
Ensembl chr 2:209,518,948...209,550,104

G

collagen type I alpha 1 chain

multiple interactions

Iron promotes the reaction [Asbestos, Amosite results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

ceruloplasmin

increases abundance
multiple interactions
increases activity
increases oxidation
increases expression
decreases export
affects binding

CP gene mutant form results in increased abundance of Iron
[Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CP protein]
Iron deficiency results in increased activity of CP promoter
CP protein results in increased oxidation of Iron
Iron deficiency results in increased expression of CP protein; Iron deficiency results in increased expression of CP protein modified form
CP gene mutant form results in decreased export of Iron
CP protein binds to [TF protein binds to Iron]
[CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; ARNT protein affects the reaction [Iron deficiency results in increased activity of CP promoter]
[CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of SLC11A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of CP protein]

PMID:10777486 PMID:12572680 PMID:16988052 PMID:19061943 PMID:20655381 More...

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

colony stimulating factor 2

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CSF2 mRNA

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

cleavage stimulation factor subunit 2, tau variant

decreases expression

Iron deficiency results in decreased expression of CSTF2T mRNA

NCBI chr 1:228,952,617...228,956,183
Ensembl chr 1:228,952,504...228,955,873

G

catenin, beta-interacting protein 1

decreases expression

Iron deficiency results in decreased expression of CTNNBIP1 mRNA

NCBI chr 5:159,961,961...160,010,942
Ensembl chr 5:159,961,928...160,010,939

G

C-X-C motif chemokine ligand 1

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CXCL1 protein

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 2

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CXCL2 protein

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome b reductase 1

decreases expression
increases expression

Iron results in decreased expression of CYBRD1 protein
Iron deficiency results in increased expression of CYBRD1 mRNA
Iron results in increased expression of CYBRD1 protein

PMID:16629162 PMID:18815723 PMID:19821111 PMID:21540277 PMID:23776592 More...

NCBI chr 3:55,934,874...55,962,132
Ensembl chr 3:55,934,874...55,962,108

G

cytochrome P450, family 2, subfamily b, polypeptide 15

decreases expression

Iron deficiency results in decreased expression of CYP2B15 mRNA

NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492

G

cytohesin 1 interacting protein

increases expression

Iron deficiency results in increased expression of CYTIP mRNA

NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993

G

death associated protein-like 1

decreases expression

Iron deficiency results in decreased expression of DAPL1 mRNA

NCBI chr 3:43,960,993...43,980,940
Ensembl chr 3:43,960,810...43,980,940

G

death-domain associated protein

increases expression

Iron results in increased expression of DAXX mRNA

NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

Iron deficiency results in increased expression of DDIT3 mRNA
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of DDIT3 mRNA

PMID:20368581 PMID:22198552

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

defensin alpha 3

decreases expression

Iron deficiency results in decreased expression of DEFA3 mRNA

NCBI chr16:70,533,436...70,535,592
Ensembl chr16:70,533,436...70,535,604

G

defensin alpha 5

increases expression

Iron deficiency results in increased expression of DEFA6 mRNA

NCBI chr16:70,342,530...70,344,854
Ensembl chr16:70,342,530...70,344,836

G

diacylglycerol kinase, alpha

increases expression

Iron deficiency results in increased expression of DGKA mRNA

NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110

G

DLC1 Rho GTPase activating protein

increases expression

Iron deficiency results in increased expression of DLC1 mRNA

NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439

G

dedicator of cytokinesis 10

increases expression

Iron deficiency results in increased expression of DOCK10 mRNA

NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525

G

dopamine receptor D1

multiple interactions

[manganese chloride co-treated with Iron deficiency] results in decreased expression of DRD1 protein

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions

[manganese chloride co-treated with Iron deficiency] results in increased expression of DRD2 protein

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

E2F transcription factor 1

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

E2F transcription factor 8

increases expression

Iron deficiency results in increased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

endothelin 1

multiple interactions

[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

eukaryotic elongation factor-2 kinase

increases expression

Iron deficiency results in increased expression of EEF2K mRNA

NCBI chr 1:175,393,119...175,456,756
Ensembl chr 1:175,393,154...175,455,164

G

epidermal growth factor receptor

multiple interactions

[Arsenic co-treated with Iron] results in decreased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

egl-9 family hypoxia-inducible factor 1

affects binding

Iron binds to EGLN1 protein

NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777

G

egl-9 family hypoxia-inducible factor 3

increases expression

Iron deficiency results in increased expression of EGLN3 mRNA

NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766

G

early growth response 1

increases expression
multiple interactions

Iron deficiency results in increased expression of EGR1 mRNA
[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of EGR1 mRNA

PMID:16629162 PMID:24619124

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

elastase, neutrophil expressed

decreases expression

Iron deficiency results in decreased expression of ELANE mRNA

NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100

G

epithelial membrane protein 1

increases expression

Iron deficiency results in increased expression of EMP1 mRNA

NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904

G

endothelial PAS domain protein 1

multiple interactions
increases expression

Iron inhibits the reaction [galangin results in increased expression of EPAS1 protein]; Iron inhibits the reaction [Quercetin results in increased expression of EPAS1 protein]
Iron deficiency results in increased expression of EPAS1 protein

PMID:17973296 PMID:23814049

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

erythropoietin

affects response to substance

Iron affects the susceptibility to EPO protein

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

exocyst complex component 6

affects metabolic processing

EXOC6 protein affects the metabolism of Iron

NCBI chr 1:235,314,612...235,457,824
Ensembl chr 1:235,300,369...235,457,015

G

coagulation factor XIII A1 chain

decreases expression

Iron deficiency results in decreased expression of F13A1 mRNA

NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700

G

coagulation factor II, thrombin

decreases activity

Iron results in decreased activity of F2 protein

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

fatty acid binding protein 2

increases expression

Iron deficiency results in increased expression of FABP2 mRNA

NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089

G

fatty acid binding protein 6

increases expression

Iron deficiency results in increased expression of FABP6 mRNA

NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282

G

family with sequence similarity 117, member B

increases expression

Iron deficiency results in increased expression of FAM117B mRNA

NCBI chr 9:61,340,284...61,418,531
Ensembl chr 9:61,340,249...61,408,483

G

FAM20C, golgi associated secretory pathway kinase

decreases expression

Iron deficiency results in decreased expression of FAM20C mRNA

NCBI chr12:15,826,864...15,885,423
Ensembl chr12:15,826,871...15,884,543

G

F-box and WD repeat domain containing 5

multiple interactions

[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of FBXW5 mRNA

NCBI chr 3:8,322,543...8,327,092
Ensembl chr 3:8,322,543...8,327,092

G

ferrochelatase

multiple interactions

[Aminolevulinic Acid results in decreased activity of FECH protein] which results in increased abundance of Iron; [Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron; [Porphobilinogen results in decreased activity of FECH protein] which results in increased abundance of Iron; heme arginate inhibits the reaction [[Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron]
[pyridoxal isonicotinoyl hydrazone results in decreased abundance of Iron] which results in decreased expression of FECH protein

PMID:15078340 PMID:30517741

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

G

flap structure-specific endonuclease 1

multiple interactions

Iron binds to and inhibits the reaction [NEIL1 protein binds to FEN1 protein]

NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003

G

flotillin 1

increases expression

Iron deficiency results in increased expression of FLOT1 mRNA

NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978

G

fructosamine 3 kinase

multiple interactions

[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of FN3K mRNA

NCBI chr10:106,700,670...106,715,903
Ensembl chr10:106,700,670...106,715,895

G

farnesyltransferase, CAAX box, subunit beta

increases expression

Iron deficiency results in increased expression of FNTB mRNA

NCBI chr 6:95,536,540...95,619,587
Ensembl chr 6:95,470,683...95,619,586

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein; [Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of FOS mRNA; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]

PMID:24619124 PMID:32828744 PMID:33580994

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

ferritin heavy chain 1

affects binding
multiple interactions
increases expression
affects metabolic processing
decreases expression
affects abundance

Iron binds to FTH1 protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA; Iron deficiency promotes the reaction [Vitamin A deficiency results in decreased expression of FTH1 protein]
Iron results in increased expression of FTH1 mRNA
FTH1 protein affects the metabolism of Iron
Iron results in decreased expression of FTH1 mRNA
FTH1 protein affects the abundance of Iron
[CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; FTH1 protein inhibits the reaction [Iron results in increased abundance of Reactive Oxygen Species]
[[NBD peptide, mouse results in decreased expression of FTH1 mRNA] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]

PMID:15893546 PMID:16424395 PMID:16448386 PMID:16988052 PMID:17070541 More...

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

multiple interactions
increases expression
decreases expression
affects binding
decreases uptake

2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]
Iron results in increased expression of FTL1 mRNA
Iron results in decreased expression of FTL1 mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA]
[CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of FTL1 mRNA]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of FTL1 mRNA]
FTL protein mutant form results in decreased uptake of Iron

PMID:12393473 PMID:12644586 PMID:15893546 PMID:16424395 PMID:16822677 More...

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

ferritin mitochondrial

multiple interactions
affects localization
affects binding

2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [diallyl trisulfide results in decreased expression of FTMT protein] which results in increased abundance of Iron; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]
FTMT protein affects the localization of Iron

PMID:12644586 PMID:16757684 PMID:21616139

NCBI chr18:45,758,874...45,760,123
Ensembl chr18:45,758,874...45,760,123

G

frataxin

increases metabolic processing
increases abundance
affects metabolic processing
affects binding

FXN protein results in increased metabolism of Iron
FXN gene mutant form results in increased abundance of Iron
FXN protein affects the metabolism of Iron
Iron binds to FXN protein

PMID:16120311 PMID:16911956 PMID:17101455 PMID:17194590

NCBI chr 1:221,874,007...221,897,543
Ensembl chr 1:221,872,420...221,897,540

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

Iron deficiency results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

gamma-aminobutyric acid type B receptor subunit 2

multiple interactions
decreases expression

[Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 protein
Iron deficiency results in decreased expression of GABBR2 mRNA; Iron deficiency results in decreased expression of GABBR2 protein

NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104

G

gamma-aminobutyric acid type A receptor subunit alpha 1

decreases expression
increases expression
multiple interactions

Iron deficiency results in decreased expression of GABRA1 mRNA
Iron deficiency results in increased expression of GABRA1 protein
[Iron deficiency co-treated with manganese chloride] results in increased expression of GABRA1 protein

NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864

G

GAR1 ribonucleoprotein

increases expression

Iron deficiency results in increased expression of GAR1 mRNA

NCBI chr 2:218,375,231...218,382,509
Ensembl chr 2:218,375,353...218,382,524

G

growth arrest-specific 1

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of GAS1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA

NCBI chr17:4,482,168...4,485,153

G

growth arrest specific 7

increases expression

Iron deficiency results in increased expression of GAS7 mRNA

NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276

G

glutamate-cysteine ligase, catalytic subunit

increases activity
decreases expression
multiple interactions

Iron results in increased activity of GCLC protein
Iron results in decreased expression of GCLC protein
leonurine inhibits the reaction [Iron results in decreased expression of GCLC protein]
Iron results in decreased expression of GCLC mRNA
Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLC mRNA]

PMID:17189828 PMID:19073151 PMID:35247364

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions
decreases expression

Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLM mRNA]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

gastrokine 1

increases expression

Iron deficiency results in increased expression of GKN1 mRNA

NCBI chr 4:119,790,101...119,795,389
Ensembl chr 4:119,790,101...119,795,389

G

gastrokine 2

increases expression

Iron deficiency results in increased expression of GKN2 mRNA

NCBI chr 4:119,778,326...119,824,366
Ensembl chr 4:119,818,280...119,824,363

G

GLI family zinc finger 3

multiple interactions

[Arsenic co-treated with Iron] results in decreased expression of GLI3 mRNA

NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712

G

glutamic-oxaloacetic transaminase 1

multiple interactions
increases activity

Capsaicin inhibits the reaction [Iron results in increased activity of GOT1 protein]; Curcumin inhibits the reaction [Iron results in increased activity of GOT1 protein]

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glycerol-3-phosphate acyltransferase, mitochondrial

increases expression

Iron deficiency results in increased expression of GPAM mRNA

NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639

G

G protein-coupled receptor 34

increases expression

Iron deficiency results in increased expression of GPR34 mRNA

NCBI chr X:9,104,829...9,113,796
Ensembl chr X:9,104,565...9,148,601

G

G protein-coupled receptor, class C, group 5, member A

increases expression

Iron deficiency results in increased expression of GPRC5A mRNA

NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260

G

glutamic--pyruvic transaminase

multiple interactions
increases activity

[ferrocene results in increased abundance of Iron] which results in increased expression of GPT protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein; Capsaicin inhibits the reaction [Iron results in increased activity of GPT protein]; Curcumin inhibits the reaction [Iron results in increased activity of GPT protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]; leonurine inhibits the reaction [Iron results in increased activity of GPT protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]
Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]

PMID:16956363 PMID:20100038 PMID:27916511 PMID:32828744 PMID:33580994 More...

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

decreases response to substance
multiple interactions

GPX1 protein results in decreased susceptibility to Iron
[Iron co-treated with Hydrogen Peroxide] results in decreased expression of and results in decreased activity of GPX1 protein

PMID:16721761 PMID:17280487

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

increases expression
affects expression

Iron deficiency results in increased expression of GPX2 mRNA
Iron affects the expression of GPX2 mRNA

PMID:16629162 PMID:24388910

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione peroxidase 4

multiple interactions
decreases expression

leonurine inhibits the reaction [Iron results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glycogen synthase kinase 3 beta

multiple interactions

[SB 216763 results in decreased activity of GSK3B protein] results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions
affects activity
decreases expression
decreases activity

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GSR protein; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of GSR protein]
Iron affects the activity of GSR protein
Iron results in decreased expression of GSR protein
[Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of GSR protein; leonurine inhibits the reaction [Iron results in decreased expression of GSR protein]
Iron results in decreased activity of GSR protein

PMID:12067571 PMID:12504893 PMID:17176674 PMID:20020847 PMID:24388910 More...

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione synthetase

multiple interactions
decreases expression

Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GSS mRNA]

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

glutathione S-transferase alpha 2

multiple interactions

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in decreased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 4

multiple interactions

Iron results in increased expression of and results in increased activity of GSTA4 protein

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase alpha 5

multiple interactions

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase mu 1

decreases expression
increases expression

Iron results in decreased expression of GSTM1 protein
Iron results in increased expression of GSTM1 mRNA; Iron results in increased expression of GSTM1 protein

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase, mu 5

multiple interactions

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of GSTM3 mRNA

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

H3.4 histone, cluster member

increases methylation
multiple interactions

Iron results in increased methylation of H3-4 protein
[[Iron co-treated with Ketoglutaric Acids] results in increased activity of KDM3A protein] which results in decreased methylation of H3-4 protein

PMID:16603237 PMID:21385672

NCBI chr10:43,740,702...43,741,262

G

hepcidin antimicrobial peptide

decreases secretion
increases expression
decreases expression
affects expression
multiple interactions
affects metabolic processing

HAMP protein results in decreased secretion of Iron
Iron results in increased expression of HAMP protein
Iron results in increased expression of HAMP mRNA
Iron deficiency results in decreased expression of HAMP mRNA
Iron affects the expression of HAMP mRNA
[Acetaminophen results in decreased expression of HAMP mRNA] which results in increased abundance of Iron; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of HAMP mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of HAMP mRNA]
HAMP protein affects the metabolism of Iron
[IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein]

PMID:11113132 PMID:16460831 PMID:16574947 PMID:16648237 PMID:17116712 More...

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

hemoglobin alpha, adult chain 2

multiple interactions

AHSP protein binds to and affects the folding of and affects the stability of [HBA1 protein binds to Iron]

NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392

G

hemoglobin subunit beta

multiple interactions
affects abundance

[HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA
HBB-B1 protein affects the abundance of Iron

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

hemoglobin, beta adult minor chain

affects abundance
multiple interactions

HBB-B2 protein affects the abundance of Iron
[HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA

NCBI chr 1:158,243,696...158,245,076
Ensembl chr 1:158,120,200...158,252,012

G

histone deacetylase 8

multiple interactions

Iron binds to and results in increased activity of HDAC8 protein

NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923

G

hephaestin

affects metabolic processing
multiple interactions

HEPH protein affects the metabolism of Iron
[Zinc results in decreased expression of HEPH protein] which results in decreased uptake of Iron

PMID:16614402 PMID:17194590

NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980

G

homeostatic iron regulator

increases uptake
affects abundance
multiple interactions
affects metabolic processing
decreases uptake
affects response to substance
increases abundance

HFE gene mutant form results in increased uptake of Iron
HFE protein affects the abundance of Iron
[HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron
HFE protein affects the metabolism of Iron
HFE protein results in decreased uptake of Iron
[HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [HFE protein binds to TFR2 protein] which affects the susceptibility to Iron; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron]
HFE protein affects the susceptibility to Iron
HFE gene polymorphism affects the abundance of Iron; HFE protein affects the abundance of Iron
HFE gene mutant form results in increased abundance of Iron; HFE gene polymorphism results in increased abundance of Iron

PMID:10085150 PMID:12393473 PMID:16793930 PMID:16823846 PMID:16841247 More...

NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
decreases expression
increases response to substance
decreases metabolic processing

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Quercetin results in decreased abundance of Iron] which results in increased expression of HIF1A protein; Iron inhibits the reaction [galangin results in increased expression of HIF1A protein]; Iron inhibits the reaction [manganese chloride results in increased expression of HIF1A protein]; Iron inhibits the reaction [Nickel results in increased stability of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of and affects the localization of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of HIF1A protein]
Iron deficiency results in decreased expression of HIF1A mRNA
HIF1A protein results in increased susceptibility to Iron
HIF1A gene mutant form results in decreased metabolism of Iron

PMID:12393473 PMID:16629162 PMID:16787915 PMID:16877034 PMID:17364964 More...

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

hemojuvelin BMP co-receptor

affects metabolic processing

HJV protein affects the metabolism of Iron

NCBI chr 2:184,065,944...184,069,851
Ensembl chr 2:184,065,970...184,069,850

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

decreases expression

Iron deficiency results in decreased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

multiple interactions
increases metabolic processing
increases expression

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of HMOX1 mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein]; leonurine promotes the reaction [Iron results in increased expression of HMOX1 protein]
HMOX1 protein results in increased metabolism of Iron
[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; [Ethanol results in increased expression of HMOX1 protein] which results in increased abundance of Iron; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; [Particulate Matter results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Iron promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron]
Iron deficiency results in increased expression of HMOX1 mRNA; Iron results in increased expression of HMOX1 protein

PMID:12393473 PMID:15602829 PMID:16439612 PMID:16629162 PMID:19136476 More...

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hematopoietic prostaglandin D synthase

increases expression

Iron deficiency results in increased expression of HPGDS mRNA

NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883

G

HRas proto-oncogene, GTPase

multiple interactions
affects localization

HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]
Iron affects the localization of HRAS protein

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

heat shock factor binding protein 1-like 1

decreases expression

Iron deficiency results in decreased expression of HSBP1L1 mRNA

NCBI chr18:73,682,286...73,690,061
Ensembl chr18:73,682,286...73,688,045

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1 like

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA1L mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family A (Hsp70) member 9

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA9 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

heat shock protein family B (small) member 1

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

heat shock protein family H (Hsp110) member 1

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPH1 mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPH1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA

PMID:12393473 PMID:22198552

NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224

G

huntingtin

decreases uptake

HTT protein mutant form results in decreased uptake of Iron

NCBI chr14:75,845,836...75,996,094
Ensembl chr14:75,845,836...75,995,070

G

intercellular adhesion molecule 1

multiple interactions

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

isopentenyl-diphosphate delta isomerase 1

decreases expression

Iron deficiency results in decreased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon gamma

multiple interactions

Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]; Iron affects the reaction [IL18 protein results in increased secretion of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

intraflagellar transport 172

increases expression

Iron deficiency results in increased expression of SLB mRNA

NCBI chr 6:25,081,933...25,121,271
Ensembl chr 6:25,081,980...25,120,860

G

insulin-like growth factor 1

multiple interactions

IGF1 protein inhibits the reaction [Carbon Tetrachloride results in increased abundance of Iron]

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 3

increases expression
multiple interactions

Iron deficiency results in increased expression of IGFBP3 mRNA
[Arsenic co-treated with Iron] results in decreased expression of IGFBP3 mRNA

PMID:16629162 PMID:31739468

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 12A

multiple interactions

Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]

NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734

G

interleukin 12B

multiple interactions

Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 18

multiple interactions

Iron affects the reaction [IL18 protein results in increased secretion of IFNG protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

multiple interactions

[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of IL1A mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
increases expression

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B protein; leonurine inhibits the reaction [Iron results in increased expression of IL1B protein]; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of IL1B protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein]
[Particulate Matter results in increased abundance of Iron] which results in increased secretion of IL1B protein

PMID:16958088 PMID:22198552 PMID:32007923 PMID:32828744 PMID:35247364

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases secretion

[IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
Iron results in increased secretion of IL6 protein
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of IL6 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of IL6 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL6 mRNA; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]

PMID:16460831 PMID:20302851 PMID:22198552 PMID:26416317 PMID:32828744 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inositol hexakisphosphate kinase 2

multiple interactions

[Arsenic co-treated with Iron] results in increased expression of IP6K2 mRNA

NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166

G

IQ motif containing D

increases expression

Iron deficiency results in increased expression of IQCD mRNA

NCBI chr12:35,955,522...35,972,420

G

iron responsive element binding protein 2

affects metabolic processing
increases activity
multiple interactions

IREB2 protein affects the metabolism of Iron
Iron deficiency results in increased activity of IREB2 protein
Clofibrate inhibits the reaction [Iron deficiency results in increased activity of IREB2 protein]

PMID:11969379 PMID:17194590

NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611

G

interferon regulatory factor 8

decreases expression

Iron deficiency results in decreased expression of IRF8 mRNA

NCBI chr19:48,790,581...48,812,363
Ensembl chr19:48,790,588...48,811,829

G

integrin subunit alpha 6

increases expression

Iron deficiency results in increased expression of ITGA6 mRNA

NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428

G

integrin subunit alpha M

increases expression
multiple interactions

Iron deficiency results in increased expression of ITGAM mRNA; Iron deficiency results in increased expression of ITGAM protein
Vitamin D promotes the reaction [Iron deficiency results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 2

increases expression

Iron deficiency results in increased expression of ITGB2 mRNA

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

intelectin 1

multiple interactions

ITLN1 protein binds to and results in increased uptake of Iron

NCBI chr13:83,932,234...83,958,243
Ensembl chr13:83,948,124...83,958,227

G

JAZF zinc finger 1

increases expression

Iron deficiency results in increased expression of JAZF1 mRNA

NCBI chr 4:81,879,501...82,183,237
Ensembl chr 4:81,881,061...82,183,100

G

joining chain of multimeric IgA and IgM

increases expression

Iron deficiency results in increased expression of JCHAIN mRNA

NCBI chr14:19,538,927...19,547,023
Ensembl chr14:19,538,952...19,546,298

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Iron deficiency results in increased expression of JUN mRNA
[Arsenic co-treated with Iron] results in increased expression of JUN mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of JUN mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA

PMID:12393473 PMID:20368581 PMID:31739468

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily E regulatory subunit 3

increases expression

Iron deficiency results in increased expression of KCNE3 mRNA

NCBI chr 1:154,523,903...154,530,865
Ensembl chr 1:154,523,830...154,532,020

G

lysine demethylase 3A

multiple interactions

[[Iron co-treated with Ketoglutaric Acids] results in increased activity of KDM3A protein] which results in decreased methylation of H3-4 protein

NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073

G

KIT proto-oncogene receptor tyrosine kinase

decreases expression

Iron deficiency results in decreased expression of KIT mRNA

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

kelch domain containing 7B

increases expression

Iron deficiency results in increased expression of KLHDC7B mRNA

NCBI chr 7:120,452,081...120,455,737
Ensembl chr 7:120,453,932...120,455,737

G

laminin subunit gamma 2

increases expression

Iron deficiency results in increased expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

lysosomal-associated membrane protein family, member 5

decreases expression

Iron deficiency results in decreased expression of LAMP5 mRNA

NCBI chr 3:123,372,462...123,384,973
Ensembl chr 3:123,372,462...123,384,952

G

lipocalin 2

affects metabolic processing
increases expression

LCN2 protein affects the metabolism of Iron
Iron results in increased expression of LCN2 mRNA; Iron results in increased expression of LCN2 protein

PMID:17194590 PMID:17350462

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

DNA ligase 3

decreases activity

Iron results in decreased activity of LIG3 protein

NCBI chr10:67,717,808...67,741,141
Ensembl chr10:67,717,812...67,798,414

G

lysyl oxidase

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of LOX mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

lysophosphatidic acid receptor 1

decreases expression

Iron deficiency results in decreased expression of LPAR1 mRNA

NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895

G

leucine rich repeat containing 25

increases expression

Iron deficiency results in increased expression of LRRC25 mRNA

NCBI chr16:18,806,888...18,813,723
Ensembl chr16:18,806,890...18,813,671

G

lymphotoxin alpha

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of LTA mRNA

NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859

G

lymphocyte antigen 75

decreases expression

Iron deficiency results in decreased expression of LY75 mRNA

NCBI chr 3:44,764,702...44,852,219
Ensembl chr 3:44,765,122...44,852,374

G

lysophospholipase 1

decreases expression

Iron deficiency results in decreased expression of LYPLA1 mRNA

NCBI chr 5:14,679,605...14,708,774
Ensembl chr 5:14,679,606...14,708,746

G

monoamine oxidase A

decreases expression

Iron deficiency results in decreased expression of MAOA mRNA

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Hydrogen Peroxide inhibits the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of MAP1LC3B protein]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]

PMID:25301941 PMID:34826546

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase 6

multiple interactions
increases phosphorylation

Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAP2K6 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

mitogen-activated protein kinase kinase kinase 14

multiple interactions

MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]

NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523

G

mitogen activated protein kinase kinase kinase 7

multiple interactions
increases activity
affects localization

Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased activity of MAP3K7 protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein]
Iron affects the localization of MAP3K7 protein

NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; [teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK1 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]
[ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Arsenic results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:11306436 PMID:16728372 PMID:17172471 PMID:23100159 PMID:30914277 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein; [teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK3 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]
[ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein
[Iron co-treated with Arsenic] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]

PMID:11306436 PMID:16728372 PMID:17172471 PMID:23100159 PMID:30914277 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

myristoylated alanine rich protein kinase C substrate

increases expression

Iron deficiency results in increased expression of MARCKS mRNA

NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012

G

mast cell-expressed membrane protein 1

increases expression

Iron deficiency results in increased expression of MCEMP1 mRNA

NCBI chr12:1,721,781...1,727,350
Ensembl chr12:1,718,730...1,725,986

G

mucolipin TRP cation channel 1

multiple interactions
increases expression

[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA; [Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 protein]
Iron results in increased expression of MCOLN1 mRNA; Iron results in increased expression of MCOLN1 protein

NCBI chr12:1,560,341...1,574,252
Ensembl chr12:1,560,359...1,574,252

G

multiple C2 and transmembrane domain containing 1

increases expression

Iron deficiency results in increased expression of MCTP1 mRNA

NCBI chr 2:6,071,408...6,761,833
Ensembl chr 2:6,065,808...6,761,833

G

malic enzyme 1

increases expression

Iron deficiency results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

macrophage migration inhibitory factor

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of MIF mRNA

NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504

G

myo-inositol oxygenase

affects binding

[MIOX protein binds to Iron] which binds to Inositol

NCBI chr 7:120,405,031...120,407,529
Ensembl chr 7:120,405,031...120,407,537

G

microRNA 196b

multiple interactions

[Air Pollutants, Occupational results in increased abundance of Iron] which results in increased expression of MIR196B mRNA

NCBI chr 4:81,330,487...81,330,571
Ensembl chr 4:81,330,487...81,330,571

G

matrix metallopeptidase 1

multiple interactions

[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

myeloperoxidase

multiple interactions
increases activity

[Hexachlorocyclohexane co-treated with Iron] results in increased activity of MPO protein
Iron results in increased activity of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

membrane spanning 4-domains A6A

decreases expression

Iron deficiency results in decreased expression of MS4A6A mRNA

NCBI chr 1:208,401,465...208,414,831
Ensembl chr 1:208,401,466...208,414,758

G

membrane spanning 4-domains A7

increases expression

Iron deficiency results in increased expression of MS4A7 mRNA

NCBI chr 1:207,969,117...207,984,743
Ensembl chr 1:207,968,761...207,983,260

G

metallothionein 1

increases expression
multiple interactions

Iron deficiency results in increased expression of MT1A; Iron deficiency results in increased expression of MT1A mRNA
ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]
[Zinc co-treated with Iron] results in increased expression of and affects the localization of MT1A protein; Iron results in increased expression of and affects the localization of MT1A protein

PMID:16629162 PMID:17241390 PMID:21852364 PMID:23776592 PMID:24089420

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

metallothionein 2A

multiple interactions
affects abundance
increases expression

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA
MT2A gene SNP affects the abundance of Iron
Iron deficiency results in increased expression of MT2 mRNA
[Zinc co-treated with Iron] results in increased expression of and affects the localization of MT2A protein; Iron results in increased expression of and affects the localization of MT2A protein
Iron deficiency results in increased expression of MT2A mRNA

PMID:12393473 PMID:16629162 PMID:17241390 PMID:21328412 PMID:24089420

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mevalonate diphosphate decarboxylase

increases expression

Iron deficiency results in increased expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

N-myc downstream regulated 1

multiple interactions

[di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron] which results in increased expression of NDRG1 protein; NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron]

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

NADH:ubiquinone oxidoreductase core subunit S1

affects expression

Iron affects the expression of NDUFS1 protein

NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893

G

neural precursor cell expressed, developmentally down-regulated 9

increases expression

Iron deficiency results in increased expression of NEDD9 mRNA

NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019

G

nei-like DNA glycosylase 1

multiple interactions

Curcumin inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Edetic Acid inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Iron binds to and affects the folding of and results in decreased activity of NEIL1 protein; Iron binds to and inhibits the reaction [NEIL1 protein binds to FEN1 protein]; Iron binds to and inhibits the reaction [NEIL1 protein binds to POLB protein]

NCBI chr 8:57,550,142...57,556,884
Ensembl chr 8:57,550,147...57,556,258

G

nei-like DNA glycosylase 2

multiple interactions

Iron binds to and results in decreased activity of NEIL2 protein

NCBI chr15:37,444,676...37,454,863
Ensembl chr15:37,445,381...37,454,863

G

NFE2 like bZIP transcription factor 2

multiple interactions
affects localization
increases activity

[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of NFE2L2 mRNA; leonurine promotes the reaction [Iron affects the localization of NFE2L2 protein]
[Particulate Matter results in increased abundance of Iron] which affects the localization of NFE2L2 protein; [Particulate Matter results in increased abundance of Iron] which results in increased expression of NFE2L2 mRNA
Iron results in increased activity of NFE2L2 promoter
NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron]

PMID:20302851 PMID:21303654 PMID:21643505 PMID:26419736 PMID:35247364

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor I/B

multiple interactions

[Arsenic co-treated with Iron] results in decreased expression of NFIB mRNA

NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479

G

nuclear factor, interleukin 3 regulated

increases expression

Iron deficiency results in increased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

NFKB inhibitor alpha

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein]; [Copper co-treated with Diethylnitrosamine co-treated with Iron] results in decreased expression of NFKBIA mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NFKBIA mRNA; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of NFKBIA protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein]
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]

PMID:17172471 PMID:20302851 PMID:33285147

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

neuroglobin

decreases uptake

NGB protein results in decreased uptake of Iron

NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830

G

NLR family, CARD domain containing 4

increases expression

Iron deficiency results in increased expression of NLRC4 mRNA

NCBI chr 6:20,991,785...21,018,254
Ensembl chr 6:20,995,266...21,018,248

G

N-myristoyltransferase 2

multiple interactions

[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of NMT2 mRNA

NCBI chr17:74,917,833...74,964,788
Ensembl chr17:74,917,833...74,961,080

G

nitric oxide synthase 2

multiple interactions

[Aluminum co-treated with Iron] results in increased expression of NOS2 protein; [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of NOS2 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NOS2 mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of NOS2 mRNA; [teferrol results in increased abundance of Iron] which results in increased expression of NOS2 mRNA
Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 mRNA]; Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 protein]

PMID:11461780 PMID:16728372 PMID:20302851 PMID:22198552 PMID:35307918

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPC intracellular cholesterol transporter 1

decreases abundance

NPC1 gene mutant form results in decreased abundance of Iron

NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049

G

NAD(P)H quinone dehydrogenase 1

increases reduction
multiple interactions
increases expression

NQO1 protein results in increased reduction of Iron
leonurine promotes the reaction [Iron results in increased expression of NQO1 protein]
[Particulate Matter results in increased abundance of Iron] which results in increased expression of NQO1 mRNA

PMID:17178108 PMID:26419736 PMID:35247364

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

occludin

multiple interactions

Iron inhibits the reaction [Lead results in decreased expression of OCLN mRNA]; Iron inhibits the reaction [Lead results in decreased expression of OCLN protein]

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

ornithine decarboxylase 1

multiple interactions
increases activity

Iron affects the reaction [3-chloroperbenzoic acid results in increased activity of ODC1 protein]; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Hydrogen Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [mezerein results in increased activity of ODC1 protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ODC1 protein]
Iron results in increased activity of ODC1 protein

PMID:7653998 PMID:12065085 PMID:12067571 PMID:12504893

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

opsin 3

decreases expression

Iron deficiency results in decreased expression of OPN3 mRNA

NCBI chr13:87,589,333...87,619,847
Ensembl chr13:87,589,333...87,619,847

G

oxysterol binding protein-like 11

increases expression

Iron deficiency results in increased expression of OSBPL11 mRNA

NCBI chr11:67,533,669...67,616,795
Ensembl chr11:67,533,672...67,596,444

G

purinergic receptor P2X 7

increases expression

Iron deficiency results in increased expression of P2RX7 mRNA

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

prolyl 4-hydroxylase subunit alpha 1

increases expression

Iron deficiency results in increased expression of P4HA1 mRNA

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

prolyl 4-hydroxylase, transmembrane

multiple interactions

Iron inhibits the reaction [manganese chloride results in decreased activity of P4HTM protein]

NCBI chr 8:109,274,629...109,292,802
Ensembl chr 8:109,274,626...109,292,473

G

poly (ADP-ribose) polymerase 1

multiple interactions

[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; [ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]

PMID:30626086 PMID:31678598 PMID:34826546

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

polycomb group ring finger 5

increases expression

Iron deficiency results in increased expression of PCGF5 mRNA

NCBI chr 1:234,063,854...234,180,022
Ensembl chr 1:234,063,892...234,175,315

G

phosphoenolpyruvate carboxykinase 1

decreases expression

Iron deficiency results in decreased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

proliferating cell nuclear antigen

increases expression
multiple interactions

Iron deficiency results in increased expression of PCNA mRNA
[taxifolin co-treated with [Iron-Dextran Complex results in increased abundance of Iron]] results in increased expression of PCNA protein

PMID:16629162 PMID:32828744

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

phosphatidylcholine transfer protein

decreases expression

Iron deficiency results in decreased expression of PCTP mRNA

NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867

G

platelet derived growth factor subunit A

multiple interactions

Iron promotes the reaction [Asbestos, Amosite results in increased expression of PDGFA mRNA]

PMID:11306436 PMID:12475806

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

pyruvate dehydrogenase kinase 4

increases expression

Iron deficiency results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

multiple interactions

[cobaltous chloride results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA

NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634

G

phosphoethanolamine/phosphocholine phosphatase 1

decreases expression

Iron deficiency results in decreased expression of PHOSPHO1 mRNA

NCBI chr10:80,762,062...80,769,596
Ensembl chr10:80,760,792...80,770,342

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta

increases expression

Iron deficiency results in increased expression of PIK3C2B mRNA

NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein]

PMID:32828744 PMID:33580994

NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

Pim-1 proto-oncogene, serine/threonine kinase

increases expression

Iron deficiency results in increased expression of PIM1 mRNA

NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174

G

phosphatidylinositol-4-phosphate 5-kinase type 1 beta

increases expression

Iron deficiency results in increased expression of PIP5K1B mRNA

NCBI chr 1:221,907,220...222,183,672
Ensembl chr 1:221,914,159...222,183,672

G

phospholipase A2 group IB

increases expression

Iron deficiency results in increased expression of PLA2G1B mRNA

NCBI chr12:41,142,193...41,151,967
Ensembl chr12:41,142,200...41,153,226

G

phospholipase A2 group 4A

decreases expression

Iron deficiency results in decreased expression of PLA2G4A mRNA

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

phospholipase A2, activating protein

decreases expression

Iron deficiency results in decreased expression of PLAA mRNA

NCBI chr 5:109,428,600...109,460,373
Ensembl chr 5:109,428,265...109,460,282

G

phospholipase D family, member 4

decreases expression

Iron deficiency results in decreased expression of PLD4 mRNA

NCBI chr 6:131,818,860...131,827,457
Ensembl chr 6:131,818,860...131,826,376

G

phospholipid phosphatase 1

increases expression

Iron deficiency results in increased expression of PLPP1 mRNA

NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268

G

phospholipid scramblase 1

decreases expression

Iron deficiency results in decreased expression of PLSCR1 mRNA

NCBI chr 8:92,784,279...92,804,698
Ensembl chr 8:92,784,356...92,804,692

G

peripheral myelin protein 22

increases expression
multiple interactions

Iron deficiency results in increased expression of PMP22 mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of PMP22 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of PMP22 mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA

PMID:12393473 PMID:16629162 PMID:20368581

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

phosphomevalonate kinase

increases expression

Iron deficiency results in increased expression of PMVK mRNA

NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364

G

pancreatic lipase

increases expression

Iron deficiency results in increased expression of PNLIP mRNA

NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654

G

pancreatic lipase-related protein 1

increases expression

Iron deficiency results in increased expression of PNLIPRP1 mRNA

NCBI chr 1:257,867,885...257,883,514
Ensembl chr 1:257,867,885...257,883,514

G

pancreatic lipase related protein 2

decreases expression

Iron deficiency results in decreased expression of PNLIPRP2 mRNA

NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434

G

protein O-glucosyltransferase 2

increases expression

Iron deficiency results in increased expression of POGLUT2 mRNA

NCBI chr 9:46,256,388...46,268,714
Ensembl chr 9:46,256,390...46,268,532

G

DNA polymerase beta

multiple interactions

Iron binds to and inhibits the reaction [NEIL1 protein binds to POLB protein]

NCBI chr16:69,379,438...69,402,710
Ensembl chr16:69,379,400...69,404,812

G

RNA polymerase III subunit E

multiple interactions

[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of POLR3E mRNA

NCBI chr 1:175,466,091...175,494,679
Ensembl chr 1:175,466,127...175,494,667

G

paraoxonase 1

multiple interactions

[Iron co-treated with Ascorbic Acid] results in decreased activity of PON1 protein; [Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein; Butylated Hydroxytoluene inhibits the reaction [[Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein]

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

cytochrome p450 oxidoreductase

multiple interactions

[[Iron co-treated with POR protein] results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; [[Iron co-treated with POR protein] results in increased metabolism of Paraquat] which results in increased abundance of Hydroxyl Radical; [Iron co-treated with POR protein] results in increased metabolism of Diquat; [Iron co-treated with POR protein] results in increased metabolism of Paraquat

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

peroxisome proliferator-activated receptor gamma

increases expression

Iron deficiency results in increased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory subunit 16B

increases expression

Iron deficiency results in increased expression of PPP1R16B mRNA

NCBI chr 3:147,323,652...147,419,658
Ensembl chr 3:147,324,126...147,418,937

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

increases expression

Iron deficiency results in increased expression of PPP1R1B mRNA

NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775

G

proteoglycan 3, pro eosinophil major basic protein 2

decreases expression

Iron deficiency results in decreased expression of PRG3 mRNA

NCBI chr 3:70,071,970...70,078,103
Ensembl chr 3:70,072,497...70,078,102

G

protein kinase AMP-activated catalytic subunit alpha 1

decreases expression

Iron deficiency results in decreased expression of PRKAA1 mRNA

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

prion protein

multiple interactions
decreases abundance

[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein; Edetic Acid inhibits the reaction [[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein]; Iron, Dietary inhibits the reaction [PRNP gene mutant form results in decreased abundance of Iron]

PMID:16595185 PMID:23478311

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

proteinase 3

decreases expression

Iron deficiency results in decreased expression of PRTN3 mRNA

NCBI chr 7:9,822,123...9,831,300
Ensembl chr 7:9,822,122...9,831,944

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of PTGS2 protein; leonurine inhibits the reaction [Iron results in increased expression of PTGS2 protein]
[Arsenic co-treated with Iron] results in increased expression of PTGS2 mRNA

PMID:20302851 PMID:31739468 PMID:35247364

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

parathyroid hormone-like hormone

multiple interactions

[Arsenic co-treated with Iron] results in increased expression of PTHLH mRNA

NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847

G

pentraxin 3

increases expression

Iron deficiency results in increased expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

peroxidasin

multiple interactions

[Arsenic co-treated with Iron] results in decreased expression of PXDN mRNA

NCBI chr 6:46,580,749...46,658,345
Ensembl chr 6:46,580,761...46,658,345

G

RAB30, member RAS oncogene family

decreases expression

Iron deficiency results in decreased expression of RAB30 mRNA

NCBI chr 1:146,803,719...146,898,369
Ensembl chr 1:146,803,714...146,892,181

G

ras related dexamethasone induced 1

multiple interactions

Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]

NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186

G

retinol binding protein 7

increases expression

Iron deficiency results in increased expression of RBP7 mRNA

NCBI chr 5:159,889,723...159,894,338
Ensembl chr 5:159,889,723...159,894,339

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
affects localization

[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; U 0126 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]
Iron affects the localization of RELA protein
[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; leonurine inhibits the reaction [Iron affects the localization of RELA protein]

PMID:33285147 PMID:33580994 PMID:35247364

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RELB proto-oncogene, NF-kB subunit

increases expression

Iron deficiency results in increased expression of RELB mRNA

NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507

G

resistin

increases expression

Iron deficiency results in increased expression of RETN mRNA

NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620

G

regulator of G-protein signaling 1

increases expression

Iron deficiency results in increased expression of RGS1 mRNA

NCBI chr13:56,018,546...56,022,889
Ensembl chr13:56,018,554...56,022,984

G

regulator of G-protein signaling 2

increases expression

Iron deficiency results in increased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

rhodopsin

multiple interactions

[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA]

NCBI chr 4:148,975,597...148,988,693
Ensembl chr 4:148,980,611...148,985,773

G

ras homolog family member B

increases expression

Iron deficiency results in increased expression of RHOB mRNA

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

ribonuclease A family member 4

increases expression

Iron deficiency results in increased expression of RNASE4 mRNA

NCBI chr15:24,312,765...24,330,112
Ensembl chr15:24,312,464...24,330,117

G

rhophilin associated tail protein 1-like

decreases expression

Iron deficiency results in decreased expression of ROPN1L mRNA

NCBI chr 2:82,442,645...82,453,332
Ensembl chr 2:82,441,891...82,453,485

G

retinoid isomerohydrolase RPE65

multiple interactions

[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA]

NCBI chr 2:248,766,497...248,798,403
Ensembl chr 2:248,766,612...248,798,403

G

ribosomal protein L37

decreases expression

Iron results in decreased expression of RPL37 mRNA

NCBI chr 2:54,215,469...54,217,429
Ensembl chr 2:54,215,469...54,217,442

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

[Iron co-treated with Oxygen] binds to RRM2 protein

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

RT1 class II, locus Bb

increases expression

Iron deficiency results in increased expression of RT1-BB mRNA

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class II, locus Db1

increases expression

Iron deficiency results in increased expression of RT1-DB1 mRNA

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

G

S100 calcium binding protein A9

decreases expression

Iron deficiency results in decreased expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

stearoyl-Coenzyme A desaturase 2

increases expression
decreases expression

Iron deficiency results in increased expression of SCD2 mRNA
Iron deficiency results in decreased expression of SCD2 mRNA

PMID:16629162 PMID:19821111

NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232

G

sterol carrier protein 2

decreases expression

Iron deficiency results in decreased expression of SCP2 mRNA

NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287

G

selectin E

multiple interactions

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

serpin family B member 8

increases expression

Iron deficiency results in increased expression of SERPINB8 mRNA

NCBI chr13:23,626,936...23,650,277
Ensembl chr13:23,626,945...23,650,835

G

sestrin 3

decreases expression

Iron deficiency results in decreased expression of SESN3 mRNA

NCBI chr 8:11,133,822...11,189,436
Ensembl chr 8:11,133,678...11,185,842

G

sirtuin 1

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

spindle and kinetochore associated complex subunit 1

increases expression

Iron deficiency results in increased expression of SKA1 mRNA

NCBI chr18:67,794,722...67,805,037
Ensembl chr18:67,794,725...67,805,037

G

solute carrier family 11 member 1

multiple interactions

[CP gene mutant form results in increased abundance of Iron] which results in increased expression of SLC11A1 mRNA

NCBI chr 9:75,957,193...75,968,115
Ensembl chr 9:75,957,316...75,968,101

G

solute carrier family 11 member 2

multiple interactions
increases uptake
affects abundance
increases expression
increases transport
decreases expression
decreases uptake
affects metabolic processing
decreases transport

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]; cupric chloride inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]; Dronabinol inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; ebselen inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; prolinedithiocarbamate inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]
SLC11A2 gene SNP affects the abundance of Iron
Iron deficiency results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein
SLC11A2 protein alternative form results in increased uptake of Iron; SLC11A2 protein results in increased uptake of Iron
SLC11A2 protein results in increased transport of Iron
Iron results in decreased expression of SLC11A2 protein
SLC11A2 gene mutant form results in decreased uptake of Iron; SLC11A2 protein mutant form results in decreased uptake of Iron
SLC11A2 protein affects the metabolism of Iron
Iron deficiency results in increased expression of SLC11A2 mRNA; Iron deficiency results in increased expression of SLC11A2 protein; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein
[Doxorubicin results in increased expression of SLC11A2 protein] which results in increased uptake of Iron; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of manganese chloride]; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of Manganese]; Manganese promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Metals promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]; SLC11A2 protein affects the reaction [Manganese results in increased transport of Iron]
SLC11A2 gene mutant form results in decreased transport of Iron
[Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein; [SLC11A2 protein mutant form results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; [Staurosporine results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC11A2 protein]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 protein]

PMID:11439223 PMID:12220667 PMID:12388109 PMID:12393473 PMID:15157939 More...

NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145

G

solute carrier family 12 member 2

increases expression

Iron deficiency results in increased expression of SLC12A2 mRNA

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

G

solute carrier family 23 member 2

increases expression

Iron deficiency results in increased expression of SLC23A2 mRNA

NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343

G

solute carrier family 26 member 11

increases expression

Iron deficiency results in increased expression of SLC26A11 mRNA

NCBI chr10:104,613,498...104,635,873
Ensembl chr10:104,613,564...104,635,970

G

solute carrier family 2 member 5

decreases expression

Iron deficiency results in decreased expression of SLC2A5 mRNA

PMID:16629162 PMID:20368581

NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106

G

solute carrier family 34 member 2

decreases expression

Iron deficiency results in decreased expression of SLC34A2 mRNA

NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436

G

solute carrier family 39 member 14

increases uptake
increases import
increases expression
multiple interactions

SLC39A14 protein results in increased uptake of Iron
SLC39A14 protein results in increased import of Iron
Iron results in increased expression of SLC39A14 mRNA; Iron results in increased expression of SLC39A14 protein
4,7-diphenylphenanthroline sulfonate inhibits the reaction [SLC39A14 protein results in increased uptake of Iron]; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 protein]

PMID:16950869 PMID:22898811 PMID:24569067

NCBI chr15:45,376,806...45,423,549
Ensembl chr15:45,376,917...45,423,524

G

solute carrier family 39 member 8

increases import
multiple interactions

SLC39A8 protein results in increased import of Iron
Cobalt inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Iron inhibits the reaction [SLC39A8 protein results in increased import of Zinc]; Iron results in increased expression of and affects the localization of SLC39A8 protein; Manganese inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Zinc inhibits the reaction [SLC39A8 protein results in increased import of Iron]
Iron inhibits the reaction [SLC39A8 protein results in increased uptake of Zinc]; Protons affects the reaction [SLC39A8 protein results in increased import of Iron]

PMID:22898811 PMID:27956349

NCBI chr 2:224,171,787...224,319,326
Ensembl chr 2:224,256,654...224,319,129

G

solute carrier family 40 member 1

multiple interactions
decreases expression
increases expression
increases export
decreases export
affects metabolic processing

[HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 mRNA]; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 protein]; NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron]; SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased uptake of Iron]
Iron results in decreased expression of SLC40A1 protein
Iron deficiency results in increased expression of SLC40A1 mRNA
[CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein]; Iron inhibits the reaction [SLC40A1 protein results in increased export of Manganese]
SLC40A1 protein mutant form results in increased export of Iron; SLC40A1 protein results in increased export of Iron
SLC40A1 protein mutant form results in decreased export of Iron
SLC40A1 protein affects the metabolism of Iron
Iron deficiency results in increased expression of SLC40A1 mRNA; Iron results in increased expression of SLC40A1 mRNA

PMID:16457665 PMID:16565419 PMID:16648237 PMID:17018382 PMID:17194590 More...

NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481

G

solute carrier family 6 member 1

multiple interactions
increases expression
decreases expression

[Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 protein; [Iron deficiency co-treated with manganese chloride] results in increased expression of SLC6A1 mRNA
Iron deficiency results in increased expression of SLC6A1 mRNA
Iron deficiency results in decreased expression of SLC6A1 protein

NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293

G

solute carrier family 6 member 3

multiple interactions

[manganese chloride co-treated with Iron deficiency] results in decreased expression of SLC6A3 protein

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

secretory leukocyte peptidase inhibitor

decreases expression

Iron deficiency results in decreased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

small integral membrane protein 3

increases expression

Iron deficiency results in increased expression of SMIM3 mRNA

NCBI chr18:53,930,019...53,982,339
Ensembl chr18:53,930,020...53,957,416

G

small nuclear RNA activating complex, polypeptide 1

increases expression

Iron deficiency results in increased expression of SNAPC1 mRNA

NCBI chr 6:92,684,785...92,710,772
Ensembl chr 6:92,684,752...92,707,746

G

synuclein alpha

multiple interactions
increases response to substance
affects localization

Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; Hydroxyurea promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Iron]
EUK-189 results in decreased susceptibility to [Iron co-treated with Paraquat co-treated with SNCA gene mutant form]
Iron affects the localization of SNCA protein

PMID:12401952 PMID:14535945 PMID:21039522 PMID:27324791

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

superoxide dismutase 1

multiple interactions
affects abundance

SOD1 protein inhibits the reaction [Asbestos, Crocidolite results in increased uptake of Iron]
[Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD1 protein]
SOD1 protein affects the abundance of Iron
[Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]

PMID:16272461 PMID:17194920 PMID:19482077 PMID:22534743

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
affects abundance

Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]; SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]
[Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD2 protein]
SOD2 protein polymorphism affects the abundance of Iron
Iron results in decreased expression of and results in decreased activity of SOD2 protein

PMID:18760346 PMID:19063909 PMID:22534743

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sorbitol dehydrogenase

affects abundance

SORD protein affects the abundance of Iron

NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133

G

sortilin 1

increases expression

Iron deficiency results in increased expression of SORT1 mRNA

NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354

G

SRY-box transcription factor 9

increases expression

Iron deficiency results in increased expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

Sp1 transcription factor

multiple interactions

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

Sp6 transcription factor

increases expression

Iron deficiency results in increased expression of SP6 mRNA

NCBI chr10:82,005,518...82,009,699
Ensembl chr10:82,005,294...82,011,013

G

sepiapterin reductase

increases expression

Iron deficiency results in increased expression of SPR mRNA

NCBI chr 4:117,671,948...117,676,292
Ensembl chr 4:117,671,949...117,675,678

G

sequestosome 1

multiple interactions

[Arsenic co-treated with Iron] results in increased expression of SQSTM1 mRNA; [Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of SQSTM1 protein]

PMID:25301941 PMID:31739468

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

Iron promotes the reaction [Arsenic results in increased phosphorylation of and results in increased activity of SRC protein]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

signal sequence receptor subunit 1

multiple interactions

[Arsenic co-treated with Iron] results in decreased expression of SSR1 mRNA

NCBI chr17:26,833,720...26,861,821
Ensembl chr17:26,833,741...26,861,821

G

STEAP2 metalloreductase

increases reduction
increases uptake

STEAP2 protein results in increased reduction of Iron
STEAP2 protein results in increased uptake of Iron

NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791

G

STEAP3 metalloreductase

affects metabolic processing
increases uptake
increases reduction

STEAP3 protein affects the metabolism of Iron
STEAP3 protein results in increased uptake of Iron
STEAP3 protein results in increased reduction of Iron

PMID:16609065 PMID:17194590

NCBI chr13:31,351,954...31,397,344
Ensembl chr13:31,351,954...31,396,519

G

STEAP4 metalloreductase

increases reduction
increases uptake

STEAP4 protein results in increased reduction of Iron
STEAP4 protein results in increased uptake of Iron

NCBI chr 4:26,077,182...26,099,859
Ensembl chr 4:26,054,671...26,099,859

G

serine/threonine kinase 11

multiple interactions

STK11 protein affects the reaction [resveratrol results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]]

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

G

sulfatase 2

increases expression

Iron deficiency results in increased expression of SULF2 mRNA

NCBI chr 3:154,822,079...154,904,566
Ensembl chr 3:154,822,085...154,904,415

G

TLR adaptor interacting with endolysosomal SLC15A4

decreases expression

Iron deficiency results in decreased expression of TASL mRNA

NCBI chr X:50,403,962...50,423,141
Ensembl chr X:50,361,248...50,423,269

G

telomerase reverse transcriptase

increases activity

Iron results in increased activity of TERT protein

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

testin LIM domain protein

increases expression

Iron deficiency results in increased expression of TES mRNA

NCBI chr 4:45,365,304...45,403,829
Ensembl chr 4:45,365,285...45,403,829

G

transferrin

multiple interactions
affects binding
increases expression
increases uptake
affects metabolic processing

[Aluminum binds to TF protein] which results in decreased uptake of Iron; [Iron binds to TF protein] which results in decreased uptake of Iron; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Iron; ammonium ferric sulfate promotes the reaction [TF protein results in increased uptake of Iron]; cobaltous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; cuprous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; ferric ammonium citrate inhibits the reaction [TF protein results in increased uptake of Iron]; ferric chloride promotes the reaction [TF protein results in increased uptake of Iron]; ferrous sulfate promotes the reaction [TF protein results in increased uptake of Iron]; gallium nitrate promotes the reaction [TF protein results in increased uptake of Iron]; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and affects the transport of Iron; zinc chloride inhibits the reaction [TF protein results in increased uptake of Iron]
[Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein; CP protein binds to [TF protein binds to Iron]; Iron binds to TF protein; TF protein binds to Iron
Iron deficiency results in increased expression of TF protein
[Iron deficiency co-treated with Manganese] results in increased expression of TF protein; [Melatonin results in increased expression of TF protein] which affects the abundance of Iron; [S-Adenosylmethionine results in increased expression of TF protein] which affects the abundance of Iron; Copper deficiency results in decreased expression of [Iron binds to TF protein]
TRF protein affects the metabolism of Iron

PMID:2039817 PMID:2308257 PMID:8782865 PMID:11193083 PMID:11335103 More...

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

trefoil factor 1

increases expression

Iron deficiency results in increased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

transferrin receptor 2

multiple interactions
decreases expression
affects metabolic processing
increases uptake
affects response to substance

[HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of TFR2 protein]
Iron deficiency results in decreased expression of TFR2 protein
TFR2 protein affects the metabolism of Iron
TFR2 protein mutant form results in increased uptake of Iron
TFR2 protein affects the susceptibility to Iron
[HFE protein binds to TFR2 protein] which affects the susceptibility to Iron

PMID:16893896 PMID:16935854 PMID:17018382 PMID:17194590 PMID:17241880 More...

NCBI chr12:19,107,673...19,124,622
Ensembl chr12:19,107,673...19,124,591

G

transferrin receptor

increases expression
affects binding
decreases expression
increases uptake
multiple interactions
affects expression
affects metabolic processing

Iron results in increased expression of TFRC protein
Iron deficiency results in increased expression of TFRC mRNA; Iron results in increased expression of TFRC mRNA
[Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein
Iron deficiency results in increased expression of TFRC mRNA; Iron deficiency results in increased expression of TFRC protein
Iron results in decreased expression of TFRC mRNA
TFRC protein results in increased uptake of Iron
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC protein; Clofibrate inhibits the reaction [Iron deficiency results in increased expression of TFRC mRNA]
Iron affects the expression of TFRC mRNA; Iron affects the expression of TFRC protein
TFRC protein affects the metabolism of Iron
[CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [Iron co-treated with Ethanol] results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC protein; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of TFRC mRNA]
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Fluvastatin results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [GGTI 298 results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein; [TFRC protein results in increased uptake of Iron] which results in increased abundance of Lipid Peroxides; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron]

PMID:10085150 PMID:11068183 PMID:11969379 PMID:12393473 PMID:16428268 More...

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 1

multiple interactions

Iron promotes the reaction [Asbestos, Amosite results in increased expression of TGFB1 mRNA]

PMID:11306436 PMID:12475806

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta receptor 1

multiple interactions

[Arsenic co-treated with Iron] results in increased expression of TGFBR1 mRNA

NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777

G

TGFB-induced factor homeobox 1

increases expression

Iron deficiency results in increased expression of TGIF1 mRNA

NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802

G

transmembrane protein 154

increases expression

Iron deficiency results in increased expression of TMEM154 mRNA

NCBI chr 2:170,015,247...170,054,903
Ensembl chr 2:170,015,184...170,052,481

G

transmembrane protein 252

increases expression

Iron deficiency results in increased expression of TMEM252 mRNA

NCBI chr 1:222,316,982...222,321,946
Ensembl chr 1:222,316,795...222,321,943

G

transmembrane protein 45b

decreases expression

Iron deficiency results in decreased expression of TMEM45B mRNA

NCBI chr 8:29,865,276...29,910,453
Ensembl chr 8:29,865,278...29,910,453

G

transmembrane protein 86A

increases expression

Iron deficiency results in increased expression of TMEM86A mRNA

NCBI chr 1:97,595,910...97,600,260
Ensembl chr 1:97,595,842...97,600,260

G

transmembrane serine protease 6

affects abundance

TMPRSS6 gene SNP affects the abundance of Iron

PMID:19820698 PMID:19820699

NCBI chr 7:109,991,008...110,021,626
Ensembl chr 7:109,985,931...110,021,624

G

tumor necrosis factor

multiple interactions
increases uptake
decreases abundance
increases secretion
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased secretion of TNF protein]; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of TNF protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; leonurine inhibits the reaction [Iron results in increased expression of TNF protein]; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of TNF protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; TNF protein affects the transport of and results in decreased abundance of Iron; U 0126 inhibits the reaction [Iron results in increased secretion of TNF protein]
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]
TNF protein results in increased uptake of Iron
TNF protein results in decreased abundance of Iron
Iron results in increased expression of TNF mRNA; Iron results in increased expression of TNF protein
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron]

PMID:10865941 PMID:12633744 PMID:16566752 PMID:16793930 PMID:16890145 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 10

increases expression

Iron deficiency results in increased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

tubulin polymerization-promoting protein family member 3

increases expression

Iron deficiency results in increased expression of TPPP3 mRNA

NCBI chr19:33,345,897...33,349,610
Ensembl chr19:33,345,898...33,349,577

G

triggering receptor expressed on myeloid cells-like 2

increases expression

Iron deficiency results in increased expression of TREML2 mRNA

NCBI chr 9:12,694,453...12,705,379
Ensembl chr 9:12,694,697...12,705,324

G

tripartite motif-containing 27

increases expression

Iron deficiency results in increased expression of TRIM27 mRNA

NCBI chr17:43,538,282...43,550,633
Ensembl chr17:43,538,285...43,550,643

G

transient receptor potential cation channel, subfamily C, member 6

increases uptake

TRPC6 protein results in increased uptake of Iron

NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092

G

teashirt zinc finger homeobox 1

increases expression

Iron deficiency results in increased expression of TSHZ1 mRNA

NCBI chr18:77,376,399...77,452,815
Ensembl chr18:77,377,394...77,453,509

G

teashirt zinc finger homeobox 3

increases expression

Iron deficiency results in increased expression of TSHZ3 mRNA

NCBI chr 1:89,386,732...89,460,719
Ensembl chr 1:89,381,858...89,460,874

G

thioredoxin 2

multiple interactions

[3-aminopyridine-2-carboxaldehyde thiosemicarbazone binds to Iron] which results in increased oxidation of TXN2 protein

NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359

G

thioredoxin interacting protein

multiple interactions

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNIP mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNIP protein

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

thioredoxin reductase 1

multiple interactions

[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of TXNRD1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNRD1 protein

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

ubiquitin-conjugating enzyme E2E 1

decreases expression

Iron deficiency results in decreased expression of UBE2E1 mRNA

NCBI chr15:7,439,751...7,493,410
Ensembl chr15:7,439,759...7,493,400

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions

[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of UGT1A6 mRNA

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 2 family, polypeptide B1

decreases expression

Iron deficiency results in decreased expression of UGT2B17 mRNA

NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986

G

UDP glucuronosyltransferase family 2 member B15

decreases expression

Iron deficiency results in decreased expression of UGT2B15 mRNA

NCBI chr14:20,768,015...20,783,599
Ensembl chr14:20,768,015...20,783,589

G

uroporphyrinogen decarboxylase

decreases activity
multiple interactions

Iron results in decreased activity of UROD protein
Iron inhibits the reaction [Ethinyl Estradiol results in increased activity of UROD protein]

PMID:3945969 PMID:12030801

NCBI chr 5:130,464,695...130,468,783
Ensembl chr 5:130,455,217...130,468,808

G

vascular cell adhesion molecule 1

multiple interactions

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vitamin D receptor

increases expression

Iron deficiency results in increased expression of VDR mRNA

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

V-set and immunoglobulin domain containing 10 like

decreases expression

Iron deficiency results in decreased expression of VSIG10L mRNA

NCBI chr 1:93,871,487...93,880,157
Ensembl chr 1:93,851,774...93,879,566

G

WD repeat domain, phosphoinositide interacting 1

increases expression

Iron deficiency results in increased expression of WIPI1 mRNA

NCBI chr10:94,542,946...94,580,174
Ensembl chr10:94,542,946...94,579,846

G

zinc finger protein 503

increases expression

Iron deficiency results in increased expression of ZFP503 mRNA

NCBI chr15:2,313,060...2,316,848
Ensembl chr15:2,313,060...2,316,848

ferbam

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

decreases activity

ferbam results in decreased activity of HSD3B1 protein

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

transforming growth factor, beta 1

decreases activity

ferbam results in decreased activity of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

ferric ammonium citrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aconitase 1

increases activity
decreases activity

ferric ammonium citrate results in increased activity of ACO1 protein
ferric ammonium citrate results in decreased activity of ACO1 protein

PMID:11054110 PMID:18073202

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

aconitase 2

multiple interactions
increases activity

ferric ammonium citrate inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; ferric ammonium citrate inhibits the reaction [Manganese results in decreased activity of ACO2 protein]
ferric ammonium citrate results in increased activity of ACO2 protein

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

acid phosphatase 5, tartrate resistant

increases expression
multiple interactions

ferric ammonium citrate results in increased expression of ACP5 protein
Silybin inhibits the reaction [ferric ammonium citrate results in increased expression of ACP5 protein]

NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929

G

AKT serine/threonine kinase 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, biomineralization associated

multiple interactions

ferric ammonium citrate results in decreased expression of and results in decreased activity of ALPL protein; Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of and results in decreased activity of ALPL protein]

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

annexin A3

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ANXA3 protein]

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

Rho GDP dissociation inhibitor alpha

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ARHGDIA protein]

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

beclin 1

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of BECN1 protein; [Hydrogen Peroxide co-treated with [ferric ammonium citrate results in increased abundance of Iron]] results in increased expression of BECN1 protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bone morphogenetic protein 6

multiple interactions

ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]; ferric ammonium citrate inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

caspase 3

increases cleavage
multiple interactions

ferric ammonium citrate results in increased cleavage of CASP3 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; DNM1L protein mutant form inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]

PMID:17191120 PMID:26318285 PMID:27481217

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

ferric ammonium citrate inhibits the reaction [2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone results in decreased expression of CDKN1A protein]
ferric ammonium citrate results in increased expression of CDKN1A protein

PMID:12807743 PMID:38483099

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

increases expression

ferric ammonium citrate results in increased expression of CDKN2A protein

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

collagen type I alpha 1 chain

decreases expression

ferric ammonium citrate results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

dynamin 1-like

multiple interactions
decreases phosphorylation

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Cyclosporine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Deferoxamine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; DNM1L protein mutant form inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; ferric ammonium citrate results in decreased phosphorylation of and affects the localization of DNM1L protein; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Tacrolimus inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]

PMID:26318285 PMID:27481217

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein]

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

endoplasmic reticulum protein 29

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ERP29 protein]

NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376

G

coagulation factor III, tissue factor

increases expression
multiple interactions

ferric ammonium citrate results in increased expression of F3 mRNA
Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased expression of F3 mRNA]

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

ferritin heavy chain 1

multiple interactions
increases expression

ferric ammonium citrate promotes the reaction [Palmitic Acid results in increased expression of FTH1 protein]
ferric ammonium citrate results in increased expression of FTH1 protein

PMID:32283200 PMID:38483099

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

multiple interactions
increases expression

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA
ferric ammonium citrate results in increased expression of FTL protein
ferric ammonium citrate results in increased expression of FTL1 protein
ferric ammonium citrate results in increased expression of FTL1 mRNA
SLC40A1 protein inhibits the reaction [ferric ammonium citrate results in increased expression of FTL1 mRNA]

PMID:12393473 PMID:19913091 PMID:38483099

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GAPDH protein]

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

galactosidase, beta 1

increases expression

ferric ammonium citrate results in increased expression of GLB1 protein

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

glyoxalase 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GLO1 protein]

NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649

G

H2A.X variant histone

increases expression

ferric ammonium citrate results in increased expression of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hepcidin antimicrobial peptide

multiple interactions
decreases expression

Deferoxamine promotes the reaction [ferric ammonium citrate results in decreased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]; ferric ammonium citrate inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

heme oxygenase 1

increases expression
multiple interactions

ferric ammonium citrate results in increased expression of HMOX1 protein
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ferric ammonium citrate results in increased expression of HMOX1 protein]

PMID:12393473 PMID:16439612

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPA1A protein]

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1 like

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

heat shock protein family A (Hsp70) member 9

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

heat shock protein family D (Hsp60) member 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPD1 protein]

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

interleukin 1 beta

multiple interactions

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of IL6 mRNA]; ferric ammonium citrate inhibits the reaction [Ozone results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]; Thapsigargin inhibits the reaction [ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

iron responsive element binding protein 2

decreases expression
decreases activity

ferric ammonium citrate results in decreased expression of IREB2 protein
ferric ammonium citrate results in decreased activity of IREB2 protein

PMID:11054110 PMID:17469137 PMID:18073202

NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611

G

lipocalin 2

multiple interactions

ferric ammonium citrate inhibits the reaction [bathophenanthroline disulfonic acid results in decreased expression of LCN2 protein]

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Hydrogen Peroxide inhibits the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein
ferric ammonium citrate results in increased phosphorylation of MAPK1 protein

PMID:17191120 PMID:25858758

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

increases phosphorylation

ferric ammonium citrate results in increased phosphorylation of MAPK14 protein

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein
ferric ammonium citrate results in increased phosphorylation of MAPK3 protein

PMID:17191120 PMID:25858758

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitochondrial ribosomal protein S9

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of MRPS9 protein]

NCBI chr 9:45,113,554...45,172,375
Ensembl chr 9:45,113,554...45,172,375

G

metallothionein 2A

multiple interactions

[ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of MT2A mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

nuclear receptor coactivator 4

multiple interactions

ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased expression of NCOA4 protein]

NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641

G

nitric oxide synthase 2

multiple interactions

[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

O-GlcNAcase

multiple interactions

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of OGA protein]

NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359

G

prolyl 4-hydroxylase subunit alpha 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of P4HA1 protein]

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

poly (ADP-ribose) polymerase 1

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

pyruvate dehydrogenase E1 subunit beta

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PDHB protein]

NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500

G

phosphoglycerate kinase 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PGK1 protein]

NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418

G

peripheral myelin protein 22

multiple interactions

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of PMP22 mRNA

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

peptidylprolyl isomerase A

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PPIA protein]

NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

receptor for activated C kinase 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of RACK1 protein]

NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975

G

RUNX family transcription factor 2

multiple interactions
decreases expression

Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of RUNX2 protein]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

sirtuin 1

multiple interactions
decreases expression

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]
Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of SIRT1 protein]

PMID:34826546 PMID:36087815

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 11 member 1

increases expression

ferric ammonium citrate results in increased expression of SLC11A1 mRNA

NCBI chr 9:75,957,193...75,968,115
Ensembl chr 9:75,957,316...75,968,101

G

solute carrier family 11 member 2

increases expression

ferric ammonium citrate results in increased expression of SLC11A2 mRNA

NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145

G

solute carrier family 40 member 1

increases expression
multiple interactions

ferric ammonium citrate results in increased expression of SLC40A1 mRNA
SLC40A1 protein inhibits the reaction [ferric ammonium citrate results in increased expression of FTL1 mRNA]

NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481

G

superoxide dismutase 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of SOD1 mRNA]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
decreases expression

Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

transferrin

multiple interactions

ferric ammonium citrate inhibits the reaction [TF protein results in increased uptake of Iron]

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transferrin receptor 2

decreases expression

ferric ammonium citrate results in decreased expression of TFR2 protein

NCBI chr12:19,107,673...19,124,622
Ensembl chr12:19,107,673...19,124,591

G

transferrin receptor

decreases expression
multiple interactions

ferric ammonium citrate results in decreased expression of TFRC mRNA; ferric ammonium citrate results in decreased expression of TFRC protein
[ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA

PMID:11054110 PMID:12393473 PMID:16760464 PMID:18073202 PMID:25633564

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

tumor necrosis factor

multiple interactions

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression

ferric ammonium citrate results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TPD52 like 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of TPD52L1 protein]

NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109

G

voltage-dependent anion channel 2

multiple interactions

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of VDAC2 protein]

NCBI chr15:2,462,877...2,476,802
Ensembl chr15:2,463,056...2,476,553

G

X-box binding protein 1

multiple interactions

ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased expression of XBP1 protein]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

ferric oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis-associated tyrosine kinase

increases expression

ferric oxide analog results in increased expression of AATK mRNA

NCBI chr10:105,290,752...105,327,219
Ensembl chr10:105,291,585...105,327,112

G

ATP binding cassette subfamily G member 1

increases expression

ferric oxide analog results in increased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

aggrecan

increases expression

ferric oxide analog results in increased expression of ACAN mRNA

NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627

G

acetylcholinesterase

decreases activity

ferric oxide results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

acyl-CoA synthetase short-chain family member 2

increases expression

ferric oxide analog results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

adhesion G protein-coupled receptor E1

increases expression

ferric oxide analog results in increased expression of ADGRE1 mRNA

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

adrenomedullin

increases expression

ferric oxide analog results in increased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenosine A2B receptor

increases expression

ferric oxide analog results in increased expression of ADORA2B mRNA

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

angiotensin II receptor, type 2

decreases expression

ferric oxide analog results in decreased expression of AGTR2 mRNA

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

AHNAK nucleoprotein 2

increases expression

ferric oxide analog results in increased expression of AHNAK2 mRNA

NCBI chr 6:131,830,668...131,876,311

G

aryl-hydrocarbon receptor repressor

increases expression

ferric oxide analog results in increased expression of AHRR mRNA

PMID:24525745 PMID:38615722

NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673

G

androgen-induced 1

increases expression

ferric oxide analog results in increased expression of AIG1 mRNA

NCBI chr 1:8,046,430...8,269,276
Ensembl chr 1:8,046,430...8,269,084

G

AKT serine/threonine kinase 1

multiple interactions

[ferric oxide analog co-treated with Acrolein] results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

5'-aminolevulinate synthase 1

increases expression

ferric oxide analog results in increased expression of ALAS1 mRNA

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

aldehyde dehydrogenase 1 family, member A2

decreases expression

ferric oxide analog results in decreased expression of ALDH1A2 mRNA

NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107

G

aldehyde dehydrogenase 1 family, member L2

decreases expression

ferric oxide analog results in decreased expression of ALDH1L2 mRNA

NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776

G

angiopoietin 1

increases expression

ferric oxide analog results in increased expression of ANGPT1 mRNA

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin-like 2

decreases expression

ferric oxide analog results in decreased expression of ANGPTL2 mRNA

NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178

G

ankyrin repeat domain 12

decreases expression

ferric oxide analog results in decreased expression of ANKRD12 mRNA

NCBI chr 9:105,583,273...105,687,957
Ensembl chr 9:105,584,065...105,687,911

G

anillin, actin binding protein

decreases expression
increases expression

ferric oxide analog results in decreased expression of ANLN mRNA
ferric oxide analog results in increased expression of ANLN mRNA

PMID:24525745 PMID:25086211

NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538

G

annexin A3

decreases expression

ferric oxide analog results in decreased expression of ANXA3 mRNA

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

aldehyde oxidase 1

increases expression

ferric oxide analog results in increased expression of AOX1 mRNA

NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770

G

adaptor related protein complex 5 subunit beta 1

decreases expression

ferric oxide analog results in decreased expression of AP5B1 mRNA

NCBI chr 1:202,876,272...202,880,303
Ensembl chr 1:202,876,272...202,880,289

G

Rho GTPase activating protein 24

increases expression

ferric oxide analog results in increased expression of ARHGAP24 mRNA

NCBI chr14:6,800,624...7,183,877
Ensembl chr14:6,800,631...7,183,823

G

activating transcription factor 3

increases expression

ferric oxide analog results in increased expression of ATF3 protein

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

autophagy related 5

increases expression

ferric oxide analog results in increased expression of ATG5 protein

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

atos homolog A

increases expression

ferric oxide analog results in increased expression of ATOSA mRNA

NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549

G

beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)

increases expression

ferric oxide analog results in increased expression of B3GALNT1 mRNA

NCBI chr 2:153,847,297...153,877,371
Ensembl chr 2:153,846,474...153,877,332

G

Beta-1,3-galactosyltransferase 2

decreases expression

ferric oxide analog results in decreased expression of B3GALT2 mRNA

NCBI chr13:55,389,406...55,398,419
Ensembl chr13:55,389,406...55,398,419

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression
decreases expression
increases phosphorylation

bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of BAX protein]
ferric oxide results in increased expression of BAX protein
ferric oxide results in decreased expression of BAX protein
ferric oxide analog results in increased phosphorylation of BAX protein

PMID:19421372 PMID:22995439 PMID:25086211 PMID:26991130

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases phosphorylation
increases expression

ferric oxide analog results in increased phosphorylation of BCL2 protein
ferric oxide results in increased expression of BCL2 mRNA
ferric oxide analog results in increased expression of BCL2 protein

PMID:22995439 PMID:25086211 PMID:33554279

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

increases expression

ferric oxide analog results in increased expression of BCL2L11 mRNA; ferric oxide analog results in increased expression of BCL2L11 protein

PMID:24525745 PMID:25086211

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

3-hydroxybutyrate dehydrogenase 2

increases expression

ferric oxide analog results in increased expression of BDH2 mRNA

NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072

G

beclin 1

decreases expression
increases expression

ferric oxide results in decreased expression of BECN1 protein
ferric oxide analog results in increased expression of BECN1 protein

PMID:24068039 PMID:25086211

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

basic helix-loop-helix family, member e40

increases expression

ferric oxide analog results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

bone morphogenetic protein 2

increases expression

ferric oxide analog results in increased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

complement C1s

increases expression

ferric oxide analog results in increased expression of C1S mRNA

NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303

G

calnexin

decreases expression

ferric oxide results in decreased expression of CANX protein

NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821

G

carbonic anhydrase 5B

increases expression

ferric oxide analog results in increased expression of CAR5B mRNA

NCBI chr X:30,474,697...30,534,797
Ensembl chr X:30,474,784...30,533,837

G

caspase 3

multiple interactions
affects activity
increases expression
increases cleavage

bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of CASP3 protein]
ferric oxide affects the activity of CASP3 protein
ferric oxide results in increased expression of CASP3 protein modified form
ferric oxide results in increased cleavage of CASP3 protein

PMID:19421372 PMID:26991130 PMID:33554279

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

ferric oxide results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cytosolic arginine sensor for mTORC1 subunit 1

increases expression

ferric oxide analog results in increased expression of CASTOR1 mRNA

NCBI chr14:79,086,136...79,090,549
Ensembl chr14:79,086,136...79,090,548

G

catalase

decreases activity
decreases expression

ferric oxide results in decreased activity of CAT protein
ferric oxide results in decreased expression of CAT protein

PMID:19699289 PMID:26991130 PMID:28993115

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 85B

increases expression

ferric oxide analog results in increased expression of CCDC85B mRNA

NCBI chr 1:202,763,645...202,764,660
Ensembl chr 1:202,763,631...202,764,703

G

C-C motif chemokine ligand 11

multiple interactions
increases expression

ferric oxide results in increased expression of and results in increased secretion of CCL11 protein; RAG1 promotes the reaction [ferric oxide analog results in increased expression of CCL11 protein]

PMID:34982504 PMID:36935073

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

increases secretion
increases expression

ferric oxide results in increased secretion of CCL2 protein
ferric oxide analog results in increased expression of CCL2 mRNA

PMID:24885771 PMID:38615722

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression

ferric oxide analog results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 22

increases secretion

ferric oxide results in increased secretion of CCL22 protein

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 3

increases secretion
multiple interactions
increases expression

ferric oxide results in increased secretion of CCL3 protein
ferric oxide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]
ferric oxide results in increased expression of CCL3 protein

PMID:24885771 PMID:35872045 PMID:36416909

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

decreases expression
increases expression
increases secretion

ferric oxide analog results in decreased expression of CCL4 mRNA
ferric oxide results in increased expression of CCL4 protein
ferric oxide results in increased secretion of CCL4 protein

PMID:24525745 PMID:24885771 PMID:35872045

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

increases expression

ferric oxide analog results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 7

increases secretion
increases expression
multiple interactions

ferric oxide results in increased secretion of CCL7 protein
ferric oxide analog results in increased expression of CCL7 mRNA
ferric oxide results in increased expression of and results in increased secretion of CCL7 protein; RAG1 inhibits the reaction [ferric oxide analog results in increased expression of CCL7 protein]

PMID:24885771 PMID:34982504 PMID:36935073 PMID:38615722

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

CD14 molecule

decreases expression

ferric oxide analog results in decreased expression of CD14 mRNA

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD274 molecule

increases expression

ferric oxide analog results in increased expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD74 molecule

decreases expression

ferric oxide analog results in decreased expression of CD74 mRNA

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

CD83 molecule

increases expression

ferric oxide analog results in increased expression of CD83 mRNA

PMID:24525745 PMID:25086211

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

cadherin 1

decreases expression

ferric oxide results in decreased expression of CDH1 protein
ferric oxide analog results in decreased expression of CDH1 mRNA

PMID:34982504 PMID:38615722

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin-related family member 1

increases expression

ferric oxide analog results in increased expression of CDHR1 mRNA

NCBI chr16:12,843,436...12,863,321
Ensembl chr16:12,843,437...12,863,396

G

cyclin-dependent kinase inhibitor 1A

increases expression

ferric oxide analog results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[ferric oxide analog co-treated with Acrolein] results in decreased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

decreases expression

ferric oxide analog results in decreased expression of CDKN2A mRNA

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

centrosomal protein 83

decreases expression

ferric oxide analog results in decreased expression of CEP83 mRNA

NCBI chr 7:29,280,358...29,389,574
Ensembl chr 7:29,280,419...29,389,574

G

C-type lectin domain containing 5A

decreases expression

ferric oxide analog results in decreased expression of CLEC5A mRNA

NCBI chr 4:69,407,125...69,416,872
Ensembl chr 4:69,407,835...69,416,859

G

CDC-like kinase 4

increases expression

ferric oxide analog results in increased expression of CLK4 mRNA

NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352

G

contactin 3

decreases expression

ferric oxide analog results in decreased expression of CNTN3 mRNA

NCBI chr 4:134,841,268...135,214,460
Ensembl chr 4:134,842,266...135,125,613

G

collagen type III alpha 1 chain

decreases expression

ferric oxide analog results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type VI alpha 3 chain

increases expression

ferric oxide analog results in increased expression of COL6A3 mRNA

NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471

G

collagen type VIII alpha 1 chain

decreases expression

ferric oxide analog results in decreased expression of COL8A1 mRNA

NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424

G

cytochrome c oxidase subunit 6A2

decreases expression

ferric oxide analog results in decreased expression of COX6A2 mRNA

NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274

G

cellular retinoic acid binding protein 2

increases expression

ferric oxide analog results in increased expression of CRABP2 mRNA

NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379

G

casein kinase 1, epsilon

increases expression

ferric oxide analog results in increased expression of CSNK1E mRNA

NCBI chr 7:110,983,322...111,006,926
Ensembl chr 7:110,983,318...111,006,794

G

C-X3-C motif chemokine receptor 1

decreases expression

ferric oxide analog results in decreased expression of CX3CR1 mRNA

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

C-X-C motif chemokine ligand 1

increases expression

ferric oxide results in increased expression of CXCL1 protein
ferric oxide analog results in increased expression of CXCL1 mRNA

PMID:35872045 PMID:38615722

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

increases expression

ferric oxide analog results in increased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 3

multiple interactions
increases expression

ferric oxide results in increased expression of and results in increased secretion of CXCL1 protein
ferric oxide results in increased expression of CXCL1 protein

PMID:34982504 PMID:35872045

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 4

increases expression

ferric oxide analog results in increased expression of CXCR4 mRNA

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

ferric oxide promotes the reaction [Benzo(a)pyrene results in increased expression of and results in increased activity of CYP1A1 protein]; ferric oxide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
ferric oxide analog results in increased expression of CYP1A1 mRNA

PMID:15211619 PMID:38615722

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression

ferric oxide analog results in increased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

DNA-damage inducible transcript 3

increases expression
decreases expression

ferric oxide analog results in increased expression of DDIT3 mRNA; ferric oxide analog results in increased expression of DDIT3 protein
ferric oxide analog results in decreased expression of DDIT3 mRNA

PMID:24525745 PMID:25086211

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4

decreases expression

ferric oxide analog results in decreased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

diacylglycerol kinase, gamma

decreases expression

ferric oxide analog results in decreased expression of DGKG mRNA

NCBI chr11:78,384,212...78,579,158
Ensembl chr11:78,384,458...78,577,212

G

dedicator of cyto-kinesis 3

increases expression

ferric oxide analog results in increased expression of DOCK3 mRNA

NCBI chr 8:107,552,462...107,903,527
Ensembl chr 8:107,552,463...107,903,514

G

dual specificity phosphatase 1

decreases expression

ferric oxide analog results in decreased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 4

increases expression

ferric oxide analog results in increased expression of DUSP4 mRNA

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

eukaryotic translation elongation factor 1 alpha 1

decreases expression

ferric oxide analog results in decreased expression of EEF1A1 mRNA

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

epidermal growth factor receptor

increases phosphorylation

ferric oxide analog results in increased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

decreases expression

ferric oxide analog results in decreased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

increases expression

ferric oxide analog results in increased expression of EGR2 mRNA

PMID:24525745 PMID:25086211

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

eukaryotic translation initiation factor 2-alpha kinase 2

decreases expression

ferric oxide analog results in decreased expression of EIF2AK2 mRNA

NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971

G

enolase 2

increases expression
decreases expression

ferric oxide analog results in increased expression of ENO2 mRNA
ferric oxide analog results in decreased expression of ENO2 mRNA

PMID:24525745 PMID:25086211

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

epsin 2

increases expression

ferric oxide analog results in increased expression of EPN2 mRNA

NCBI chr10:46,197,785...46,259,673
Ensembl chr10:46,197,785...46,259,642

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

ferric oxide analog results in increased expression of and results in increased phosphorylation of ERN1 protein

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

endothelial cell-specific molecule 1

increases expression

ferric oxide analog results in increased expression of ESM1 mRNA

NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804

G

filamin binding LIM protein 1

increases expression

ferric oxide analog results in increased expression of FBLIM1 mRNA

NCBI chr 5:153,883,945...153,915,524
Ensembl chr 5:153,883,960...153,913,757

G

filamin A interacting protein 1

increases expression

ferric oxide analog results in increased expression of FILIP1 mRNA

NCBI chr 8:80,761,283...80,956,556
Ensembl chr 8:80,764,604...80,922,549

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression
increases expression

ferric oxide analog results in decreased expression of FOS mRNA
ferric oxide analog results in increased expression of FOS mRNA

PMID:24525745 PMID:25086211

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

ferric oxide analog results in increased expression of FOSB mRNA

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

FOS like 1, AP-1 transcription factor subunit

increases expression

ferric oxide analog results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

Fus RNA binding protein

decreases expression

ferric oxide analog results in decreased expression of FUS mRNA

NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414

G

FYN binding protein 1

decreases expression

ferric oxide analog results in decreased expression of FYB1 mRNA

NCBI chr 2:55,621,585...55,781,206
Ensembl chr 2:55,632,698...55,779,629

G

growth arrest and DNA-damage-inducible, alpha

increases phosphorylation

ferric oxide analog results in increased phosphorylation of GADD45A protein

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

increases expression

ferric oxide analog results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

guanylate binding protein 2

increases expression

ferric oxide analog results in increased expression of GBP2 mRNA

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

gap junction protein, alpha 1

increases expression

ferric oxide analog results in increased expression of GJA1 mRNA

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glycoprotein nmb

increases expression

ferric oxide analog results in increased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

G protein-coupled receptor 183

increases expression

ferric oxide analog results in increased expression of GPR183 mRNA

NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559

G

G protein-coupled receptor 84

decreases expression
increases expression

ferric oxide analog results in decreased expression of GPR84 mRNA
ferric oxide analog results in increased expression of GPR84 mRNA

PMID:24525745 PMID:25086211

NCBI chr 7:134,443,904...134,446,173
Ensembl chr 7:134,443,936...134,446,178

G

glutathione-disulfide reductase

multiple interactions

[Benzo(a)pyrene co-treated with ferric oxide] results in increased activity of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 1

increases expression

ferric oxide analog results in increased expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase pi 1

increases expression

ferric oxide analog results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

H2A.X variant histone

multiple interactions
increases expression

Oxygen deficiency inhibits the reaction [ferric oxide analog results in increased expression of H2AX protein]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2B clustered histone 6

decreases expression

ferric oxide analog results in decreased expression of H2BC7 mRNA

PMID:24525745 PMID:25086211

NCBI chr17:41,520,775...41,521,238

G

H2B clustered histone 9

decreases expression

ferric oxide analog results in decreased expression of H2BC9 mRNA

PMID:24525745 PMID:25086211

NCBI chr17:42,470,593...42,478,590

G

H3 clustered histone 1

decreases expression

ferric oxide analog results in decreased expression of H3C1 mRNA

NCBI chr17:41,368,379...41,368,902
Ensembl chr17:41,368,386...41,368,856
Ensembl chr17:41,368,386...41,368,856
Ensembl chr17:41,368,386...41,368,856
Ensembl chr17:41,368,386...41,368,856

G

heparin-binding EGF-like growth factor

increases expression

ferric oxide analog results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

HEAT repeat containing 3

decreases expression

ferric oxide analog results in decreased expression of HEATR3 mRNA

NCBI chr19:18,892,477...18,930,502
Ensembl chr19:18,893,144...18,930,509

G

heme binding protein 1

increases expression

ferric oxide analog results in increased expression of HEBP1 mRNA

NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854

G

hypoxia inducible lipid droplet-associated

increases expression

ferric oxide analog results in increased expression of HILPDA mRNA

NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557

G

histone cluster 1 H2a family member I like 1

decreases expression

ferric oxide analog results in decreased expression of H3C6 mRNA

NCBI chr17:41,568,181...41,569,093
Ensembl chr17:41,568,471...41,569,109

G

histone cluster 1, H2bc

increases expression

ferric oxide analog results in increased expression of H2BC21 mRNA

NCBI chr17:42,692,335...42,696,601
Ensembl chr17:42,694,723...42,696,642

G

histone cluster 1 H4 family member B

decreases expression

ferric oxide analog results in decreased expression of HIST1H4B mRNA

NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370

G

histone cluster 2 H2B family member E

decreases expression

ferric oxide analog results in decreased expression of H2BC11 mRNA

NCBI chr 2:183,780,583...183,783,030

G

heme oxygenase 1

increases expression

ferric oxide analog results in increased expression of HMOX1 mRNA

PMID:24525745 PMID:25086211 PMID:38615722

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hydroxysteroid 11-beta dehydrogenase 1

increases expression

ferric oxide analog results in increased expression of HSD11B1 mRNA

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7

increases expression

ferric oxide analog results in increased expression of HSD3B7 mRNA

NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family D (Hsp60) member 1

decreases expression

ferric oxide results in decreased expression of HSPD1 protein

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

hyaluronidase 1

increases expression
decreases expression

ferric oxide analog results in increased expression of HYAL1 mRNA
ferric oxide analog results in decreased expression of HYAL1 mRNA

PMID:24525745 PMID:25086211

NCBI chr 8:108,250,668...108,254,519
Ensembl chr 8:108,250,667...108,260,210

G

intercellular adhesion molecule 1

increases expression

ferric oxide results in increased expression of ICAM1 protein

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

intercellular adhesion molecule 2

decreases expression

ferric oxide analog results in decreased expression of ICAM2 mRNA

NCBI chr10:91,308,608...91,319,536
Ensembl chr10:91,308,538...91,315,293

G

inhibitor of DNA binding 1

increases expression

ferric oxide analog results in increased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

inhibitor of DNA binding 3

increases expression

ferric oxide analog results in increased expression of ID3 mRNA

NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349

G

interferon, alpha-inducible protein 27 like 2A

increases expression

ferric oxide analog results in increased expression of IFI27L2B mRNA

NCBI chr 6:122,598,872...122,600,358
Ensembl chr 6:122,598,872...122,600,360

G

interleukin 10 receptor subunit alpha

decreases expression

ferric oxide analog results in decreased expression of IL10RA mRNA

NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061

G

interleukin 12B

multiple interactions

ferric oxide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 13

multiple interactions
increases expression

RAG1 promotes the reaction [ferric oxide analog results in increased expression of IL13 protein]

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 17A

multiple interactions

ferric oxide results in increased expression of and results in increased secretion of IL17A protein

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 beta

increases secretion

ferric oxide analog results in increased secretion of IL1B protein
ferric oxide results in increased secretion of IL1B protein

PMID:24525745 PMID:24885771

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor-like 2

increases expression

ferric oxide analog results in increased expression of IL1RL2 mRNA

NCBI chr 9:42,591,658...42,639,351
Ensembl chr 9:42,591,934...42,636,667

G

interleukin 2

multiple interactions

[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of IL2 protein

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 33

multiple interactions

ferric oxide results in increased expression of and results in increased secretion of IL33 protein

NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373

G

interleukin 4

multiple interactions

[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of IL4 protein; ferric oxide inhibits the reaction [Ovalbumin results in increased expression of IL4 protein]

PMID:20540983 PMID:23147377

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 4 induced 1

decreases expression

ferric oxide analog results in decreased expression of IL4I1 mRNA

NCBI chr 1:95,299,457...95,324,564
Ensembl chr 1:95,295,601...95,324,562

G

interleukin 5

multiple interactions

[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of IL5 protein; ferric oxide results in increased expression of and results in increased secretion of IL5 protein

PMID:20540983 PMID:34982504

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions
increases expression
increases secretion

[Magnetite Nanoparticles co-treated with ferric oxide] results in increased expression of IL6 protein; RAG1 promotes the reaction [ferric oxide analog results in increased expression of IL6 protein]
ferric oxide results in increased secretion of IL6 protein
ferric oxide analog results in increased secretion of IL6 protein

PMID:20540983 PMID:24525745 PMID:24885771 PMID:36935073

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interferon regulatory factor 7

decreases expression

ferric oxide analog results in decreased expression of IRF7 mRNA

NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases phosphorylation

ferric oxide analog results in increased phosphorylation of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KLF transcription factor 2

decreases expression

ferric oxide analog results in decreased expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

KLF transcription factor 4

decreases expression

ferric oxide analog results in decreased expression of KLF4 mRNA

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

kelch-like family member 31

increases expression

ferric oxide analog results in increased expression of KLHL31 mRNA

NCBI chr 8:78,515,514...78,538,873
Ensembl chr 8:78,515,514...78,538,873

G

laminin subunit alpha 3

increases expression

ferric oxide analog results in increased expression of LAMA3 mRNA

NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353

G

lysosomal-associated membrane protein 1

multiple interactions

[ferric oxide analog co-treated with Acrolein] results in decreased expression of LAMP1 protein

NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883

G

lysosomal-associated membrane protein 2

increases expression

ferric oxide analog results in increased expression of LAMP2 protein

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

galectin 3

increases expression

ferric oxide analog results in increased expression of LGALS3 mRNA

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

leukocyte immunoglobulin like receptor B4

decreases expression

ferric oxide analog results in decreased expression of LILRB4B mRNA

NCBI chr 1:69,805,020...69,810,628
Ensembl chr 1:69,805,250...69,810,660

G

LIM domain and actin binding 1

increases expression

ferric oxide analog results in increased expression of LIMA1 mRNA

NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473

G

LIM zinc finger domain containing 2

increases expression

ferric oxide analog results in increased expression of LIMS2 mRNA

NCBI chr18:23,553,937...23,592,137
Ensembl chr18:23,553,937...23,592,137

G

U6 spliceosomal RNA

decreases expression

ferric oxide analog results in decreased expression of RNU6 mRNA

NCBI chr11:16,655,090...16,655,196
Ensembl chr11:16,655,090...16,655,196

G

lysyl oxidase-like 4

increases expression

ferric oxide analog results in increased expression of LOXL4 mRNA

NCBI chr 1:241,396,183...241,416,385
Ensembl chr 1:241,397,983...241,416,322

G

leukocyte specific transcript 1

decreases expression

ferric oxide analog results in decreased expression of LST1 mRNA

NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997

G

lymphocyte antigen 6 family member A

decreases expression

ferric oxide analog results in decreased expression of LY6A mRNA

NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981

G

Ly6/Plaur domain containing 6

decreases expression

ferric oxide analog results in decreased expression of LYPD6 mRNA

NCBI chr 3:34,487,425...34,632,887
Ensembl chr 3:34,496,485...34,630,308

G

lysozyme 2

decreases expression

ferric oxide analog results in decreased expression of LYZ2 mRNA

NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106

G

MAF bZIP transcription factor B

increases expression

ferric oxide analog results in increased expression of MAFB mRNA

NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031

G

microtubule-associated protein 1 light chain 3 alpha

increases expression

ferric oxide analog results in increased expression of MAP1LC3A protein

NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670

G

microtubule-associated protein 1 light chain 3 beta

increases expression

ferric oxide analog results in increased expression of MAP1LC3B protein

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

ferric oxide analog results in increased phosphorylation of MAPK1 protein
[ferric oxide analog co-treated with Acrolein] results in increased phosphorylation of MAPK1 protein

PMID:24068039 PMID:24847785

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

ferric oxide analog results in increased phosphorylation of MAPK3 protein
[ferric oxide analog co-treated with Acrolein] results in increased phosphorylation of MAPK3 protein

PMID:24068039 PMID:24847785

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

methionine adenosyltransferase 2A

decreases expression
increases expression

ferric oxide analog results in decreased expression of MAT2A mRNA
ferric oxide analog results in increased expression of MAT2A mRNA

PMID:24525745 PMID:25086211

NCBI chr 4:104,489,877...104,495,447
Ensembl chr 4:104,488,466...104,495,493

G

myocyte enhancer factor 2C

decreases expression

ferric oxide analog results in decreased expression of MEF2C mRNA

NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880

G

multiple EGF-like-domains 6

decreases expression

ferric oxide analog results in decreased expression of MEGF6 mRNA

NCBI chr 5:164,738,272...164,839,142
Ensembl chr 5:164,738,352...164,839,139

G

microsomal glutathione S-transferase 1

increases expression

ferric oxide analog results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892